1. Introduction
===============

Pathogenic bacteria use various strategies to interact with target tissues and cells of the host organism. Among them, toxin production constitutes an efficient way to alter specific functions of target cells. Toxins can act locally or at a distance from the infectious site and are responsible for severe diseases in man and animals. While some toxins, called cytotoxins, cause disruption of all cell types, thus permitting the pathogen access to nutrients, other toxins are only active on specific cells such as enterotoxins active on epithelial intestinal cells and neurotoxins targeting neuronal cells. This is achieved by the recognition of specific cell surface receptor(s) and/or specific intracellular target(s). When bound to the receptor, toxins can unleash their toxic program at the cell membrane by interfering with signal transduction pathways, pore formation, or enzymatic activities towards membrane compounds. In contrast, other toxins enter the cytosol, recognize, and modify specific intracellular targets. According to the nature of the target and the type of modification, intracellular active toxins cause a dramatic alteration of cellular functions such as protein synthesis, cell homeostasis, cell cycle progression, vesicular traffic, and actin cytoskeletal rearrangements. The nervous system which is diffused through all the organism is one of the main target of bacterial toxins. If neurotoxins, like clostridial neurotoxins, exclusively interact with neuronal cells from the central or peripheral nervous system inducing specific neurological symptoms, other toxins recognize a broader range of cell types including neuronal cells. For example, cytotoxins can trigger necrosis or apoptosis in various cell types as well as in neuronal cells. Thereby various toxins, in addition to their specific activity on some cell types, affect certain neuronal cells, directly or indirectly, leading to neurological symptoms associated with typical clinical signs resulting from the other affected cells ([Table 1](#toxins-02-00683-t001){ref-type="table"}, and [Figure 1](#toxins-02-00683-f001){ref-type="fig"}). This review is focused on the various modes of interaction with neuronal cells of bacterial neurotoxins and other toxins affecting the nervous system.

2. The Cellular and Molecular Mechanisms Involved in Neuroexocytosis: An Overview
=================================================================================

2.1. An overview of neurotransmission
-------------------------------------

Transfer of information or command between neurons, or neurons and target cells (muscle fibers, endocrine cells, *etc*.) is most often chemical in nature and occurs at highly specialized contact sites termed *synapses*. Here, the release of neurotransmitter molecules by the presynaptic elements enables activation of receptors localized on the postsynaptic target. Neurotransmitter molecules are comprised of small organic molecules as acetylcholine (ACh), catecholamines like dopamine or noradrenaline, serotonin (5-HT), glutamate, gamma-aminobutyric acid (GABA), glycine, adenosine-triphosphate (ATP), and numerous peptides such as vaso-intestinal peptide (VIP), substance P (SP), and calcitonin gene-related protein (CGRP). Released transmitter substance(s) can activate ligand-gated ionic channels or metabotropic receptors, thus mediating either transmembrane ionic fluxes or activation of intracellular signaling pathway(s). For example, in the central nervous system, depending on the ion species flowing through the channel, activation of ligand-gated ionic channels can cause depolarization (*i.e.*, excitation) or hyperpolarization (*i.e.*, inhibition) of the postsynaptic plasma membrane, respectively, and the excitation/inhibition net balance determines eventual initiation of action potentials propagated in the neuron until the next synapses. The evoked endplate potential at muscle fibers following stimulation of the motor nerve (and subsequent ACh release) is a depolarization that may reach the threshold for initiating muscle action potential, which itself propagates along muscle fiber ultimately triggering its contraction. In the enteric nervous system, release of neurotransmitter molecules (as VIP) by mucosal nerve endings directly contacting the enterocytes, or indirectly *via* the activation of entero-chrommaffin cells releasing 5-HT, can lead to activation of metabotropic receptors, intracellular activation of the adenylate cyclase and downstream cAMP-dependent pathways, resulting in an active co-transport of ions species (Na^+^, K^+^, Cl^−^) and water efflux for osmotic compensation in the intestine lumen (viz the molecular mechanisms of diarrhoea \[[@B5-toxins-02-00683]\]).

toxins-02-00683-t001_Table 1

###### 

Bacterial neurotoxins and other toxins interacting with the nervous system.

  Toxin                                       Bacteria             Structure                             Target neuronal cell                          Receptor                                        Activity                                                  Effects                                                                      **MLD (μg/kg)^1^**
  ------------------------------------------- -------------------- ------------------------------------- --------------------------------------------- ----------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------- --------------------
  **Toxins inhibiting the neuroexocytosis**                                                                                                                                                                                                                                                                                                   
  Botulinum neurotoxins                       *C. botulinum*       single chain protein (150 kDa)        motoneurons                                   gangliosides (GD~1b~, GT~1b~)                   proteolysis of SNARE proteins (VAMP, SNAP25, syntaxin)    inhibiton of acetylcholine release (flaccid paralysis)                       0.0003
  *C. baratii*                                synaptotagmin, SV2                                                                                                                                                                                                                                                                              
  *C. butyricum*                                                                                                                                                                                                                                                                                                                              
  Tetanus neurotoxin                          *C. tetani*          single chain protein (150 kDa)        inhibitory interneurons                       gangliosides (GD~1b~, GT~1b~)                   proteolysis of SNARE protein (VAMP)                       inhibition of neurotransmitter release (GABA, glycine) (spastic paralysis)   0.001
  GPI-anchored protein                                                                                                                                                                                                                                                                                                                        
  Lethal toxin                                *C. sordellii*       single chain protein (250 kDa)        potentially all neurons                       unknown                                         inactivation of Rho and Ras-GTPases (glucosylation)       inhibition of neurotransmitter release                                       0.1
  Toxin B                                     *C. difficile*       single chain protein (250 kDa)        potentially all neurons                       unknown                                         inactivation of Rho-GTPases (glucosylation)               inhibition of neurotransmitter release                                       32
  Pneumolysin                                 *S. pneumoniae*      single chain protein (53 kDa)         hippocampal neurons                           cholesterol                                     pore-forming activity                                     neuronal apoptosis (meningitis)                                              
  Enterotoxin                                 *C. perfringens*     single chain protein (36 kDa)         enterocyte neurons                                                                            pore-forming activity                                                                                                                  80
  **Toxins stimulating neurosecretion**                                                                                                                                                                                                                                                                                                       
  Epsilon toxin                               *C. perfringens*     single chain protein (36 kDa)         hippocampal neurons                           unknown                                         pore-forming activity                                     stimulation of glutamate release (excitation)                                0.1
  Cholera toxin                               *V. cholerae*        AB5 structure                         enterochrompaffin cells and enteric neurons   ganglioside GM~1~                               inactivation of Gsα and activation of adenylate cyclase   5-HT release (diarrhea)                                                      250
  Heat labile enterotoxin                     *E. coli*            AB5 structure                         enterochromaffin cells and enteric neurons    ganglioside GM~1~                               inactivation of Gsα and activation of adenylate cyclase   5-HT release (diarrhea)                                                      250
  Toxin A                                     *C. difficile*       single chain protein (300 kDa)        enterocytes enteric neurons                   membrane glycoprotein                           inactivation of Rho-GTPases, other mechanism?             release of inflammatory mediators and neuropeptides (diarrhea)               0.35
  Heat stable enterotoxin                     *E. coli*            short peptide (2--5 kDa)              enterocyte enteric neurons?                   guanylate cyclase                               GMP~c~ increase,other mechanism?                          stimulation of enteric nervous system(diarrhea)                              
  Staphylococcal enterotoxins                 *S. aureus*          single chain protein (25--30 kDa)     enterochromaffin cells, vagal nerve           histocompatibility complex class II molecules   superantigen other mechanism?                             5-HT release stimulation of 5-HT~3~ receptor (emesis)                        20 (monkey)
  Cereulide                                   *B. cereus*          cyclic dodecadepsipeptide (1.2 kDa)   vagal nerve                                   5HT~3~ receptor                                 K^+^ ionophore                                            stimulation of 5-HT~3~ receptor (emesis)                                     

^1^Mouse lethal doses per kg of body weight according to \[[@B1-toxins-02-00683],[@B2-toxins-02-00683],[@B3-toxins-02-00683],[@B4-toxins-02-00683]\].

![Schematic representation of bacterial toxins active on the nervous system.](toxins-02-00683-g001){#toxins-02-00683-f001}

In nerve terminals, transmitter molecules are stored into at least two different classes of secretory organelles: the small lucent synaptic vesicles, and large dense core vesicles or granules. The small lucent vesicles, approximately 50 nm in diameter, contain small organic molecules and are formed by either budding from the early endosome or recycling of empty vesicles \[[@B6-toxins-02-00683],[@B7-toxins-02-00683]\]. The large dense core vesicles are analogous to the secretory granules present in endocrine and exocrine cells and have a biogenesis different from that of the synaptic vesicles. Similar to many cargo vesicles, they are formed by vesicle budding from the trans-Golgi system, followed by homotypic fusion to form larger vesicles. Usually they mediate release of peptide transmitter or certain catecholamines whose synthesis depends on the presence in the granule lumen of enzymes (as the dopamine-beta-hydroxylase). Small synaptic vesicles and certain large dense core vesicles are equipped with a vacuolar-type ATPase that creates a proton gradient which drives specific vesicular transporters, thereby allowing active uptake and storage of neurotransmitter molecules inside these vesicles. Regardless the secretory organelle size, large or small, the release of its content into the extracellular space implicates a fusion of its membrane with the plasmalemma, which then allows passive diffusion of its content into the surrounding medium. This exocytotic process is triggered by a rise in the cytosolic concentration of Ca^++^, in response either to the arrival of a propagated action potential (*i.e.*, at the neuron nerve endings) or following activation of ionotropic or/and metabotropic receptors located on the plasma membrane of secretory cells \[[@B8-toxins-02-00683]\].

2.2. Mechanisms of exocytosis and SNAREs
----------------------------------------

More than 100 proteins are implicated in Ca^++^-dependent exocytosis. However, only a dozen of them participate in the core machinery required for transmitter release, while the others serve regulatory roles \[[@B9-toxins-02-00683],[@B10-toxins-02-00683]\]. Interestingly, several proteins of the release machinery are targeted and disabled by various bacterial toxins. A large body of evidence indicates that the synaptic vesicles do not move freely within the nerve ending cytosol, and regulation of their interaction with actin-based cytoskeleton allows fine tuning of their movements \[[@B11-toxins-02-00683],[@B12-toxins-02-00683]\]. At the fusion site, they bind to the scaffold proteins associated with a special presynaptic matrix termed "active zone" \[[@B12-toxins-02-00683]\]. When tethered to the fusion site, the synaptic vesicles are not yet fusogenic and must acquire fusion competence. A key step in this process is the pairing and assembly of a fusion particle comprised of VAMP (vesicle-associated membrane protein, also termed synaptobrevin), SNAP-25, and syntaxin, on the inner face of the plasma membrane (reviewed by \[[@B9-toxins-02-00683],[@B10-toxins-02-00683]\]). These three proteins are also designed as the SNARE proteins ([s]{.ul}oluble [*N*]{.ul}-ethylmaleimide-sensitive factor [a]{.ul}ttachment protein [re]{.ul}ceptors). Munc-18 protein is the fourth essential protein partner, it participates in SNARE complexe formation and binds to it (reviewed by \[[@B9-toxins-02-00683],[@B10-toxins-02-00683]\]).The SNARE proteins or closely related isoforms are also involved in the fusion of large dense core vesicle or secretory granules. Assembly of the three SNAREs, and possibly munc-18, triggers hemifusion of vesicles and plasma membrane. Termination of fusion is triggered by a rise in intracellular Ca^++^ concentration, which may result from either Ca^++^ influx through voltage-gated channels (e.g., at nerve terminals), Ca^++^ release from intracellular stores, or both (e.g., at many neuroendocrine cells) \[[@B13-toxins-02-00683],[@B14-toxins-02-00683]\]. The principal Ca^++^sensor for triggering fusion is synaptotagmin, which is an integral synaptic vesicle protein interacting with SNAREs \[[@B10-toxins-02-00683],[@B15-toxins-02-00683],[@B16-toxins-02-00683],[@B17-toxins-02-00683]\]. Synaptotagmin is equipped with two "C2-domains", which acquire high affinity for membrane lipids upon binding to Ca^++^ ions but in a pretty high intracellular concentration (10--100 µM). Thus synaptotagmin is likely sensing the Ca^++^ changes due to activation of voltage-dependent calcium channels. Its Ca^++^-dependent interaction with plasma membrane leads to changes in membrane curvature and destabilization of the lipids permitting the fusion \[[@B18-toxins-02-00683]\]. Several SNARE/synaptotagmin complexes (possibly 4 to 6) must act synergistically to allow fusion of a synaptic vesicle (reviewed by \[[@B9-toxins-02-00683],[@B10-toxins-02-00683]\]). Recently, a role similar to that of synaptotagmin has been assigned to the Doc2 protein, given the high affinity of Doc2 for Ca^++^. Thus, Doc2 is likely intervening in spontaneous exocytosis at nerve endings and secretory cells, which is triggered/regulated by minute changes in the resting intracellular Ca^++^ concentration \[[@B19-toxins-02-00683]\].

2.3. Actin cytoskeleton and small GTPases in exocytotic mechanisms
------------------------------------------------------------------

Many other proteins play key roles in synaptic vesicle trafficking and priming of tethered synaptic vesicles. Inside nerve terminals, vesicles traffic along actin filaments and this implicates molecular motors like myosins II or V, and small GTPases of the Rab family (Rab3 and others) \[[@B20-toxins-02-00683],[@B21-toxins-02-00683]\]. Reorganization of the actin cytoskeleton is coupled to Ca^++^-regulated exocytosis in endocrine cells. However, this is far from being clear in neurons \[[@B11-toxins-02-00683],[@B22-toxins-02-00683],[@B23-toxins-02-00683]\]. The role of actin in exocytosis seems to consist in governing the vesicle-granule trafficking towards release site \[[@B22-toxins-02-00683],[@B23-toxins-02-00683]\]. Organization of the actin-based cytoskeleton is controlled by several proteins, including several small GTPases like Rho proteins \[[@B24-toxins-02-00683]\] and ADPribosylation factor (ARF). Like most small GTPases, ARF and Rho proteins cycle between GDP-bound (inactive), and GTP-bound (active) states, thereby acting as signal transducers that respond to upstream signals. Thus, they activate downstream effector molecules which carry out their biological functions. Rho proteins (Rho, Rac, Cdc42) are widely-expressed monomeric GTPases. Their translocation to specific membrane domains enables intervention of distinct biological functions, including: (1) regulation of actin cytoskeletal dynamics; (2) cell cycle progression; (3) gene transcription; (4) membrane transport; and 5) exo-/endo-cytosis \[[@B23-toxins-02-00683],[@B24-toxins-02-00683]\]. In chromaffin and PC12 cells, RhoA associates with secretory granules, whereas Rac1 and Cdc42 are found in the subplasmalemmal region \[[@B23-toxins-02-00683]\]. Activation of phosphatidylinositol 4-kinase by RhoA promotes the formation of granule-associated actin filaments and/or stabilize the subplasmalemmal actin barrier \[[@B23-toxins-02-00683]\]. In chromaffin cells, Cdc42 and Rac1 control actin polymerization and secretion \[[@B25-toxins-02-00683],[@B26-toxins-02-00683]\]. In neurons, Rac1 is associated with synaptic vesicles and plasma membrane \[[@B27-toxins-02-00683]\]. Rac1 is involved in a post-docking step of neuronal exocytosis during which it controls in an all-or-none manner the functionality of release sites \[[@B27-toxins-02-00683],[@B28-toxins-02-00683]\], possibly *via* regulation of phospholipase D (PLD) activity \[[@B29-toxins-02-00683]\]. Additional pathways converging on PLD1 implicates ARF6 GTPases \[[@B30-toxins-02-00683]\]. Ral-GTPase is abundant in nerve terminals and associates with synaptic vesicles \[[@B31-toxins-02-00683]\]. This molecule apparently plays a key role in neurotransmitter release by regulating the pool size of readily releasable synaptic vesicles \[[@B32-toxins-02-00683]\]. Ral has been implicated in regulating PLD activity too \[[@B33-toxins-02-00683]\]. Downstream from ARF6, Ral, Rho, Rac, and Cdc42, PLD produces PA. PLD is possibly activated by these GTPases upon docking of synaptic vesicles, or secretory granules, at the release sites. PLD activation is an important event for exocytosis in neurons and many secretory cell types \[[@B34-toxins-02-00683],[@B35-toxins-02-00683],[@B36-toxins-02-00683],[@B37-toxins-02-00683]\]. PLD-production of phosphatidic acid (PA) may either signal attachment of some proteins of the fusion machinery to the fusion site or play a role in vesicle fusion. Indeed, PA is a cone-shaped lipid whose local accumulation, and possibly destabilization of the lipids at the fusion site \[[@B35-toxins-02-00683],[@B36-toxins-02-00683],[@B37-toxins-02-00683]\] may promote negative curvation of the inner (cytoplasmic) plasma membrane leaflet \[[@B38-toxins-02-00683]\].

3. Toxins Inhibiting the Neuroexocytosis
========================================

3.1. Toxins which specifically impair the SNARE exocytosis mechanism: Clostridial neurotoxins
---------------------------------------------------------------------------------------------

*Clostridium* *botulinum* and *Clostridium* *tetani* secrete very potent neurotoxins, which are responsible for neurological disorders in humans and animals, botulism and tetanus, respectively. Several recent reviews detail the structure and mode of action of neurotoxins \[[@B39-toxins-02-00683],[@B40-toxins-02-00683],[@B41-toxins-02-00683],[@B42-toxins-02-00683],[@B43-toxins-02-00683],[@B44-toxins-02-00683],[@B45-toxins-02-00683]\].

*C.* *tetani* forms a homogeneous bacterial species which produces only one type of tetanus toxin (TeNT), whereas botulinum neurotoxin (BoNT)-producing strains are heterogeneous. *C.* *botulinum* is divided into 4 groups, which on the basis of phenotypic and genotypic parameters, correspond to different species. In addition, some strains of other species, such as *Clostridium* *butyricum* and *Clostridium* *baratii*, can produce a related BoNT type E and F, respectively. Seven BoNT toxinotypes (A, B, C, D, E, F, and G) are distinguished according to their antigenic properties. Each toxinotype is now divided into subtypes based on BoNT sequence variations, which can impact antibody binding and neutralization or affinity as well as catalytic efficiency for their substrate \[[@B46-toxins-02-00683],[@B47-toxins-02-00683],[@B48-toxins-02-00683],[@B49-toxins-02-00683],[@B50-toxins-02-00683],[@B51-toxins-02-00683]\].

BoNTs are associated with non-toxic proteins (ANTPs) to form large complexes. ANTPs encompass a non-toxic and non-hemagglutinin component (NTNH) and several hemagglutinin components (HA34, HA17 and HA70 in *C.* *botulinum* A) or OrfX components \[[@B44-toxins-02-00683],[@B52-toxins-02-00683]\]. Recent model and composition of BoNT complexes have been proposed \[[@B53-toxins-02-00683],[@B54-toxins-02-00683]\]. The function of ANTPs is still unclear; they could protect the neurotoxin from the acidic pH of the stomach and from digestive proteases.

### 3.1.1. Structure

BoNTs and TeNT share a common structure. They are synthesized as a precursor protein (about 150 kDa), which is inactive or weakly active. The precursor which does not contain signal peptide, is released from the bacteria possibly by a yet misunderstood cell-wall exfoliation mechanism \[[@B55-toxins-02-00683]\]. The precursor is proteolytically activated in the extra-bacterial medium either by *Clostridium* proteases or by exogenous proteases such as digestive proteases in the intestinal content. The active neurotoxin consists of a light chain (L, about 50 kDa) and a heavy chain (H, about 100 kDa), which remain linked by a disulfide bridge. The structure of BoNTs shows three distinct domains: L-chain containing α-helices and β-strands and including the catalytic zinc binding motif, the N-terminal part of the H-chain forming two unusually long and twisted α-helices, and the C-terminal part of the H-chain consisting of two distinct subdomains (H~CN~ and H~CC~) involved in the recognition of the receptor. While the three domains are arranged in a linear manner in BoNT/A and BoNT/B, both the catalytic domain and the binding domain are on the same side of the translocation domain in BoNT/E. This domain organization in BoNT/E might facilitate a rapid translocation process \[[@B56-toxins-02-00683],[@B57-toxins-02-00683],[@B58-toxins-02-00683],[@B59-toxins-02-00683],[@B60-toxins-02-00683],[@B61-toxins-02-00683],[@B62-toxins-02-00683],[@B63-toxins-02-00683],[@B64-toxins-02-00683],[@B65-toxins-02-00683]\].

The overall sequence identity at the amino acid level beween BoNTs and TeNT ranges from 34 to 97%. Several domains are highly conserved which account for the common mode of action of these toxins. Thereby, the central domains of L chains are related in all the clostridial neurotoxins and contain the consensus sequence (His-Glu-X-X-His) characteristic of zinc-metalloprotease active site. The half N-terminal domain of the H-chains is also highly conserved, and it is involved in the translocation of the L-chain into the cytosol. Thus, a similar mechanism of internalization of the intracellular active domain into target cells is shared by all the clostridial neurotoxins. In contrast, the half C-terminal parts of H-chain, mainly the H~cc~ subdomains, are the most divergent \[[@B44-toxins-02-00683],[@B52-toxins-02-00683]\]. This accounts for the different receptors recognized by the clostridial neurotoxins (see below).

### 3.1.2. Mode of action

Although BoNTs and TeNT use different routes, they display a similar intracellular mechanism of action. BoNTs enter by oral route or are produced directly in the intestine subsequently to a *C.* *botulinum* intestinal colonization and then undergo a transcytosis across the digestive mucosa \[[@B66-toxins-02-00683],[@B67-toxins-02-00683],[@B68-toxins-02-00683],[@B69-toxins-02-00683],[@B70-toxins-02-00683],[@B71-toxins-02-00683]\]. After diffusion into the extracellular fluid and blood stream circulation, BoNTs target motoneuron endings. In contrast, TeNT is formed in wounds colonized by *C.* *tetani*. TeNT diffuses in the extracellular fluid and can target all types of nervous endings (sensory, adrenergic neurons and motoneurons), but it is mainly retrogradelly transported through the motoneurons (see below) \[[@B72-toxins-02-00683],[@B73-toxins-02-00683],[@B74-toxins-02-00683]\].

Each type of BoNT and TeNT recognizes specific receptors on demyelinated terminal nerve endings, mainly through the H~CC~ subdomain. BoNT/A, /C, /E, /F exploit the three isoforms of the vesicle protein SV2 as specific receptors, while BoNT/B and /G bind to synaptotagmin I or II \[[@B75-toxins-02-00683],[@B76-toxins-02-00683],[@B77-toxins-02-00683],[@B78-toxins-02-00683],[@B79-toxins-02-00683],[@B80-toxins-02-00683],[@B81-toxins-02-00683]\]. The GPI-anchored membrane protein Thy-1 has been proposed to act as a TeNT receptor \[[@B82-toxins-02-00683],[@B83-toxins-02-00683]\], but this has not been confirmed. Ganglioside-binding sites have been characterized in the H~CC~ subdomain. Interestingly, TeNT exhibits two carbohydrate-binding sites, whereas BoNT/A and BoNT/B show only one \[[@B63-toxins-02-00683],[@B84-toxins-02-00683],[@B85-toxins-02-00683],[@B86-toxins-02-00683]\]. Accordingly, TeNT can bind simultaneously to two gangliosides \[[@B87-toxins-02-00683]\]. BoNT/C and BoNT/D interact with gangliosides (GD~1b~, GT~1b~) and phosphatidylethanolamine, respectively by their H~CC~ subdomain \[[@B88-toxins-02-00683]\]. The role of H~CN~subdomain, which may interact with phosphatidylinositol phosphates \[[@B89-toxins-02-00683]\], is still unclear. Overall, whatever the considered clostridial neurotoxin, the identified protein receptors are not neurospecific and are expressed on several cell types including intestinal crypt epithelial cells in the intestine \[[@B69-toxins-02-00683]\]. Distribution of the gangliosides recognized by BoNTs differs from that of the protein receptors. Thus, the high affinity of BoNTs and TeNT for presynaptic membranes probably results from multiple and synergistic interactions with the ganglioside and protein parts of receptor, and binding to gangliosides which induces conformational changes in the Hc domain, probably facilitates subsequent binding to protein receptor \[[@B90-toxins-02-00683],[@B91-toxins-02-00683]\]. Co-presence of the *ad hoc* ganglioside(s) and protein receptors likely facilitates the identification of cell subset targeted by TeNT or BoNTs at very low concentrations encountered in the physiological medium during the disease. At higher concentrations, binding to the protein receptor is likely sufficient for mediating toxin binding. Indeed the number of cell types affected by these toxins expands with increasing toxin concentrations. Therefore, BoNTs can target numerous neurons but not all, as well as non-neuronal cells at high concentrations, inhibiting the release of various compounds ([Table 2](#toxins-02-00683-t002){ref-type="table"}).
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###### 

Clostridial neurotoxins block the release of many different neurotransmitters and other molecules in neuronal and in some non-neuronal cells. However, the release of certain neurotransmitters is resistant to BoNTs, either the target cells do not express the specific receptor(s) for BoNT entry or the intracellular target (SNARE protein) do not contain BoNT cleavage site.

  Neurotransmitter                                                                                      Model system                                                                                                                  References
  ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  **Blockage of neurotransmitter and other molecule release by BoNTs in neuronal cells**                                                                                                                                              
  Acetylcholine (ACh)                                                                                   Skeletal muscular junction                                                                                                    \[[@B92-toxins-02-00683]\]
  Torpedo electric organ                                                                                \[[@B93-toxins-02-00683]\]                                                                                                    
  Aplysia, CNS                                                                                          \[[@B94-toxins-02-00683]\]                                                                                                    
  Glutamate                                                                                             Brain synaptosome                                                                                                             \[[@B95-toxins-02-00683]\]
  Hind paw/mass spectrometry                                                                            \[[@B96-toxins-02-00683]\]                                                                                                    
  Cultured rat cerebellar neurons/radioassay                                                            \[[@B97-toxins-02-00683]\]                                                                                                    
  Cultured rat cerebellar neurons/enzymatic assay                                                       \[[@B98-toxins-02-00683]\]                                                                                                    
  Aspartate                                                                                             Brain synaptosomes                                                                                                            \[[@B99-toxins-02-00683]\]
  Gamma aminobutyric acid (GABA)                                                                        Brain synaptosomes                                                                                                            \[[@B99-toxins-02-00683],[@B100-toxins-02-00683]\]
  Glycine                                                                                               Spinal cord neurons (culture)                                                                                                 \[[@B101-toxins-02-00683]\]
  Dopamine                                                                                              Brain synaptosomes                                                                                                            \[[@B100-toxins-02-00683],[@B102-toxins-02-00683]\]
  Adrenalin                                                                                                                                                                                                                           
  Noradrenalin                                                                                                                                                                                                                        
  Serotonin (or 5-HT)                                                                                   Brain synaptosomes                                                                                                            \[[@B103-toxins-02-00683]\]
  ATP corelease with ACh                                                                                Torpedo synaptosomes                                                                                                          \[[@B104-toxins-02-00683]\]
  Rat bladder urothelium                                                                                \[[@B105-toxins-02-00683],[@B106-toxins-02-00683]\]                                                                           
  Guinea pig stellate neurons                                                                           \[[@B107-toxins-02-00683]\]                                                                                                   
  Nicotinamide adenine dinucleotide (NAD)                                                               Canine mesenteric artery                                                                                                      \[[@B108-toxins-02-00683]\]
  Human urinary bladder detrusor muscle                                                                 \[[@B109-toxins-02-00683]\]                                                                                                   
  **Effects on other neuropeptides**                                                                                                                                                                                                  
  Substance P (SP)                                                                                      Inhibition of KCl evoked SP release                                                                                           
  Calcitonin gene-related peptide (CGRP)                                                                Inhibition of release in cultured dorsal root ganglia (DRG) neurons                                                           \[[@B110-toxins-02-00683],[@B111-toxins-02-00683]\]
  Inhibition of release in cultured rat bigeninal nerve cells                                           \[[@B112-toxins-02-00683]\]                                                                                                   
  Rat bladder afferent neurons                                                                          \[[@B113-toxins-02-00683]\]                                                                                                   
  Upregulation and increase of CGRP                                                                     \[[@B114-toxins-02-00683],[@B115-toxins-02-00683],[@B116-toxins-02-00683],[@B117-toxins-02-00683]\]                           
  **Neurotransmitter release resistant to BoNTs**                                                                                                                                                                                     
  Vaso intestinal peptide (VIP), CGRP                                                                   Periglandular innervation of sweat glands                                                                                     \[[@B118-toxins-02-00683]\]
  Neuropeptide Y                                                                                        Vasoconstrictor neurons afferent to vena cava and uterine artery from guinea pig                                              \[[@B119-toxins-02-00683]\]
  SP                                                                                                    Capsain evoked release from cultured DRG                                                                                      \[[@B110-toxins-02-00683]\]
  Nitric oxide (NO) Ach                                                                                 Non vesicular fraction of 5-HT evoked ACh release at bronchiolar smooth muscle (ACh release by epithelial cells ?)            \[[@B119-toxins-02-00683],[@B120-toxins-02-00683],[@B121-toxins-02-00683]\]
  GABA                                                                                                  Cultured inhibitory hippocampal interneurons (BoNT-resistant SNAP25 related isoform ?)                                        \[[@B122-toxins-02-00683]\]
  **Blockage of the process release in non-neuronal cells by BoNTs at high concentrations (≥100 nM)**                                                                                                                                 
  Catecholamines                                                                                        Chromaffin cells                                                                                                              \[[@B123-toxins-02-00683],[@B124-toxins-02-00683],[@B125-toxins-02-00683]\]
  ATP, glutamate                                                                                        Glial cells: astrocytes or Schwann cells                                                                                      \[[@B126-toxins-02-00683],[@B127-toxins-02-00683],[@B128-toxins-02-00683]\]
  Insulin                                                                                               Pancreatic beta-cells                                                                                                         \[[@B129-toxins-02-00683]\]
  Store-mediated Ca^++^ entry                                                                           Exocrine pancreas cells                                                                                                       \[[@B130-toxins-02-00683]\]
  Store-mediated Ca^++^ entry                                                                           Platelets                                                                                                                     \[[@B131-toxins-02-00683]\]
  **Blockage of neurotransmitter by TeNT**                                                                                                                                                                                            
  Glycine                                                                                               Cat, rat spinal cord                                                                                                          \[[@B132-toxins-02-00683],[@B133-toxins-02-00683]\]
  Murine spinal cord cell cultures (complete blockage of evoked and spontaneous release)                \[[@B134-toxins-02-00683]\]                                                                                                   
  GABA                                                                                                  Rat brain                                                                                                                     \[[@B135-toxins-02-00683]\]
  Pig cerebrocortical synaptosomes                                                                      \[[@B99-toxins-02-00683]\]                                                                                                    
  Rat hippocampal slices                                                                                \[[@B136-toxins-02-00683],[@B137-toxins-02-00683],[@B138-toxins-02-00683]\]                                                   
  Cerebellar cell cultures                                                                              \[[@B139-toxins-02-00683]\]                                                                                                   
  Glutamate                                                                                             Murine spinal cord cell cultures (partial blockage of evoked release and increase in spontaneous release)                     \[[@B134-toxins-02-00683]\]
  Rat brain                                                                                             \[[@B140-toxins-02-00683]\]                                                                                                   
  Cerebellar neuronal cells                                                                             \[[@B141-toxins-02-00683]\]                                                                                                   
  Pig cerebrocortical synaptosomes                                                                      \[[@B99-toxins-02-00683],[@B142-toxins-02-00683]\]                                                                            
  Cultured hippocampal neurons (blockage of AMPA receptor insertion *via* SNARE-dependent exocytosis)   \[[@B143-toxins-02-00683],[@B144-toxins-02-00683]\]                                                                           
  Synaptosomes                                                                                          \[[@B142-toxins-02-00683]\]                                                                                                   
  Aspartate                                                                                             Pig cerebrocortical synaptosomes                                                                                              \[[@B99-toxins-02-00683]\]
  Brain synaptosomes                                                                                    \[[@B138-toxins-02-00683]\]                                                                                                   
  Brain slices                                                                                          \[[@B145-toxins-02-00683]\]                                                                                                   
  Synaptosomes (no inhibition of evoked aspartate release)                                              \[[@B142-toxins-02-00683]\]                                                                                                   
  Catecholamines                                                                                        Cultured brain neurons                                                                                                        \[[@B146-toxins-02-00683]\]
  Chromaffin cells                                                                                      \[[@B147-toxins-02-00683],[@B148-toxins-02-00683],[@B149-toxins-02-00683],[@B150-toxins-02-00683],[@B151-toxins-02-00683]\]   
  Synaptosomes                                                                                          \[[@B152-toxins-02-00683],[@B153-toxins-02-00683]\]                                                                           
  Rat brain                                                                                                                                                                                                                           
  Serotonin                                                                                             Rat brain                                                                                                                     \[[@B152-toxins-02-00683],[@B153-toxins-02-00683]\]
  Synaptosomes                                                                                          \[[@B154-toxins-02-00683]\]                                                                                                   
  Synaqptosomes (inhibition of serotonin uptake)                                                        \[[@B155-toxins-02-00683],[@B156-toxins-02-00683],[@B157-toxins-02-00683],[@B158-toxins-02-00683]\]                           
  Acetylcholine                                                                                         Chromaffin PC12 cells                                                                                                         \[[@B159-toxins-02-00683],[@B160-toxins-02-00683]\]
  Synaptosomes                                                                                          \[[@B161-toxins-02-00683],[@B162-toxins-02-00683]\]                                                                           
  Aplysia californica neurons (intraneural injection)                                                   \[[@B163-toxins-02-00683]\]                                                                                                   
  Met-enkephalin                                                                                        Pig cerebrocortical synaptosomes                                                                                              \[[@B99-toxins-02-00683]\]
  **Blockage of exocytosis in non neuronal cells by TeNT**                                                                                                                                                                            
  Glutamate                                                                                             Astrocytes                                                                                                                    \[[@B164-toxins-02-00683]\]
  Transferrin receptor                                                                                  CHO cell (cleavage of cellubrevin)                                                                                            \[[@B165-toxins-02-00683]\]

Neurotoxin bound to its receptor is internalized by receptor-mediated endocytosis. An essential difference between both types of neurotoxins is that BoNTs are directly endocytosed in clathrin-coated vesicles, which, when acidified, trigger the translocation of the L chain into the cytosol. Therefore, BoNT L chain is delivered in the peripheral nervous system, to neuromuscular junctions where it blocks the release of acetylcholine leading to a flaccid paralysis. In contrast, TeNT enters different endocytic vesicles, which are not acidified. The vesicles retrogradely transport the toxin in a microtubule-dependent manner to the cell body of neurons in the spinal cord. Like nerve growth factors, TeNT is transported by tubulo-vesicular organelles characterized by the presence of neurotrophin receptor such as p75^NTR^\[[@B166-toxins-02-00683],[@B167-toxins-02-00683],[@B168-toxins-02-00683],[@B169-toxins-02-00683],[@B170-toxins-02-00683],[@B171-toxins-02-00683]\]. The C-terminal fragment of TeNT drives the retrograde transport of the toxin, and can be used to transport heterologous protein in the same way \[[@B172-toxins-02-00683],[@B173-toxins-02-00683]\]. Then, TeNT carries out a transynaptic migration and reaches the target neurons, which are inhibitory interneurons involved in the regulation of the motoneurons. TeNT enters target inhibitory interneurons *via* vesicles that are acidified thus permitting the delivery of the L chain into the cytosol, where it inhibits the regulated release of glycine and GABA. Acidification of the vesicle lumen triggers a conformational change of the neurotoxin and subsequent translocation of the L chain into the cytosol. H chains form tetramers and insert into lipid membranes, thus forming cation selective channels permeable to small molecules (\<700 Da). The mechanism of translocation is not completely understood. The N-terminal part of H chain mediates the translocation of L chain into the cytosol at acidic endosomal pH by modifying the electrostatic interactions with the phospholipids without detectable conformational changes. In addition, the disulfide bond between the two chains has a crucial role in the translocation process \[[@B174-toxins-02-00683],[@B175-toxins-02-00683],[@B176-toxins-02-00683],[@B177-toxins-02-00683]\]. Then, the L chain refolds in the neutral pH of the cytosol. Cytosolic translocation factors such as β-COPI are possibly involved in this mechanism, as it has been found for diphtheria toxin \[[@B41-toxins-02-00683],[@B43-toxins-02-00683],[@B45-toxins-02-00683],[@B178-toxins-02-00683]\].

L chains of all clostridial neurotoxins are zinc-metalloproteases that cleave one of the three members of the SNARE proteins. TeNT and BoNT/B, D, F and G attack synaptobrevin (or VAMP), BoNT/A and E cleaves SNAP25, and BoNT/C1 cut both SNAP25 and syntaxin. The cleavage sites are different for each neurotoxin except BoNT/B and TeNT, which proteolyse synaptobrevin at the same site. Cleavage of SNARE proteins occurs only when disassembled. Since VAMP, SNAP25, and syntaxin play a major role in the regulated fusion of synaptic vesicles with the plasma membrane at the release sites, their cleavage induces a blockade of the neurotransmitter exocytosis ([Figure 2](#toxins-02-00683-f002){ref-type="fig"}).

SNAP25 cleavage by BoNT/A or BoNT/E deeply decreases both SNAP25 and Ca^++^ binding to synaptotagmin, and subsequently the fusion process of exocytosis ([Figure 2](#toxins-02-00683-f002){ref-type="fig"}) \[[@B179-toxins-02-00683],[@B180-toxins-02-00683],[@B181-toxins-02-00683],[@B182-toxins-02-00683]\]. Removal of the nine C-terminal amino acids of SNAP-25 by BoNT/A deeply disrupts the coupling between Ca^++^ sensing and the final step in exocytosis \[[@B180-toxins-02-00683]\]. Truncated SNAP-25 can behave as a dominant negative mutant upon the exocytotic process suggesting that after BoNT/A treatment, the block of release is due to both functional elimination of SNAP-25 and accumulation of the cleavage product which competitively inhibits exocytosis \[[@B183-toxins-02-00683],[@B184-toxins-02-00683],[@B185-toxins-02-00683]\]. In contrast, blockade of exocytosis by BoNT/E is only due to cleavage of SNAP-25, not to the production of competitive antagonists of SNARE complex formation. Indeed, inhibition of exocytosis by BoNT/E can be rescued by supplementing the C-terminal portion of SNAP-25 removed by the toxin \[[@B186-toxins-02-00683],[@B187-toxins-02-00683],[@B188-toxins-02-00683]\]. Truncation of SNAP-25 by BoNT/E destabilizes the four-helix bundle of the SNARE complex \[[@B186-toxins-02-00683],[@B187-toxins-02-00683]\], and SNAP-25 truncated by BoNT/E is not retained by syntaxin \[[@B189-toxins-02-00683]\].

![Schematic representation of the molecular mechanism of evoked neuroexocytosis and of toxin-dependent inhibition of neurotransmitter release. Clostridial neurotoxins are assumed to enter neuronal cells *via* synaptic vesicle recycling or by classical receptor-dependent endocytosis like *C. sordellii* LT. Acidification of the endosomal lumen triggers the translocation of the catalytic domain (L chain of clostridial neurotoxins or N-terminal domain of LT) into the cytosol. Synaptic vesicles loaded with neurotransmitter move from a reserve zone to the "active zone" in a close proximity to the release sites through an actin filament-dependent manner. Synaptic vesicles association with release sites is first driven by interaction of the vesicular GTPase Rab3 with the plasma membrane-associated protein Rim (tethering). Subsequent activation of Munc18, which triggers the de-chaperonning of syntaxin, leads to SNARE complex assembly (priming/docking). Ca^++^ entry is sensed by synpatotagmin and triggers the fusion event and release of neurotransmitter through Rac-PLD1 activation. Clostridial neurotoxin L chains have access to the cleavage sites of SNARE proteins when the SNARE proteins are dissociated (physiological window). Cleavage of SNAP25 by BoNT/A or BoNT/C, SNARE complex formation still occurs. But, the release of the C-terminal domain of SNAP25 impairs the interaction between SNAP25 and Ca^++^ to synaptotagmin thus preventing the fusion. Truncation of SNAP25 by BoNT/E or VAMP by BoNT/B, BoNT/D, BoNT/F or TeNT destabilizes or leads to non functional SNARE complexes. LT acts differently by glucosylating and thus inactivating Rac and subsequently preventing the PLD1 production of fusogenic phosphatidic acid.](toxins-02-00683-g002){#toxins-02-00683-f002}

VAMP cleavage abolishes the interaction of VAMP with the adaptor protein AP3 and affect synaptic vesicle recycling *via* early endosomes \[[@B190-toxins-02-00683]\]. The SNARE cleavage products have also the potential to interfere with fusion processes \[[@B179-toxins-02-00683],[@B191-toxins-02-00683]\]. Consistent with synaptophysin-1 controlling specifically the targeting of VAMP2 but not VAMP1 to synaptic vesicles, is the observation that the cytosolic cleavage product of VAMP2 but not VAMP1, released upon TeNT or BoNT/B activity, blocks the neurotransmitter release \[[@B191-toxins-02-00683]\]. This result suggests an alteration of the exocytosis due to a disturbance of synaptophysin-1/VAMP2 interaction and of coupling between detecting Ca^++^ and synaptic vesicle triggering \[[@B180-toxins-02-00683]\]. Since the synaptic vesicles docked with unproductive complexes cannot fuse or undock, they stay at the fusion sites (with slightly increased numbers) irreversibly plugging the fusion sites that would normally accommodate intact vesicles. This progressively reduces the number of release sites to which exocytosis can occur as recently demonstrated for TeNT at identified *Aplysia* cholinergic synapses \[[@B36-toxins-02-00683]\]. When VAMP is cleaved by TeNT, BoNT/B or /G, the VAMP portion (\~20 amino acids) remaining in the synaptic vesicle membrane does not contain interaction sites for the other SNAREs. Therefore, the synaptic vesicle membrane is no longer linked to a SNARE complex, and fusion with the plasma membrane cannot occur. When VAMP is cleaved by BoNT/D or /F, the C-terminal fragment remaining in the vesicle membrane is long enough to anchor the synaptic vesicle to the SNARE complex, but fusion cannot occur because the SNARE complex cannot transit into the thermally stable four-helix bundle ([Figure 2](#toxins-02-00683-f002){ref-type="fig"}).

BoNT/C cleaves both syntaxin-1 and SNAP-25, but *in vitro* cleavage of SNAP-25 by BoNT/C occurs with low efficiency (\~1000-fold difference) versus cleavage by BoNT/A or /E \[[@B192-toxins-02-00683],[@B193-toxins-02-00683]\]. This raises the question which of the two targets is involved in BoNT/C neuroexocytosis blockade? In squid giant synapses, BoNT/C cleaves syntaxin-1, but not SNAP25 \[[@B194-toxins-02-00683]\], whereas in cultured hippocampal slices or spinal neurons from mammal, BoNT/C efficiently removes nearly all SNAP25 \[[@B195-toxins-02-00683],[@B196-toxins-02-00683]\]. Thus, depending on the cell type, the secretory blockade is likely due to syntaxin and/or SNAP-25 cleavage. Upon syntaxin cleavage, SNARE complexes are formed, but loosely docked to plasma membrane, thus synaptic vesicles remain tethered to plasma membrane and cannot fuse \[[@B44-toxins-02-00683]\].

Although the physiological properties induced by the cleavage of either VAMP, SNAP25 or syntaxin are not equivalent at the neuromuscular junctions, all the clostridial neurotoxins cause a blockade of the regulated neurotransmission, which varies in intensity and duration according to each neurotoxin type. TeNT and BoNT/B share the same molecular mechanism. They are translocated in different subset of neurons (excitatory neuron: BoNTs \>\> TeNT; inhibitory neurons: TeNT \>\> BoNTs) produce strongly different symptoms. This induces different clinical signs (TeNT: spastic paralysis; BoNTs: flaccid paralysis). Indeed the peripheral dysautonomia and flaccid paralysis caused by BoNTs result from preferential inhibition of acetylcholine release. In the spinal chord or facial motor nuclei, TeNT-mediated blockade of glycine or GABA release disrupts the negative controls exerted by the inhibitory interneurons onto the motoneurons turning on excessive firing of the motoneurons and ensuing muscle contraction \[[@B42-toxins-02-00683],[@B44-toxins-02-00683],[@B45-toxins-02-00683],[@B197-toxins-02-00683]\].

### 3.1.3. Duration of intoxication

The main factor governing the duration of intoxication is the BoNT toxinotype. The half-lives of exocytosis blockade in rat cerebellum neurons are more than 31 days for BoNT/A, more than 25 days for BoNT/C1, about 10 days for BoNT/B, about two days for BoNT/F and less than one day for BoNT/E, and these durations correlates with the paralysis duration \[[@B97-toxins-02-00683],[@B198-toxins-02-00683],[@B199-toxins-02-00683]\]. The factors governing the toxin longevity within the nerve terminals are not fully unraveled, yet presence of a N-terminal sequence and a C-terminal dileucine motif in BoNT/A L chain, and not in the other toxinotypes, may explain the retention of BoNT/A L chain to the plasma membrane \[[@B200-toxins-02-00683]\]. Other factors should be considered: in contrast to BoNT/E truncation, SNAP25 lacking nine C-terminal residues, released by BoNT/A proteolysis, remains localized at the membrane in association with syntaxin. Therefore, unproductive SNARE complex at the active zone induces long-term impeding of synaptic vesicle fusion, whereas SNAP25 cleaved by BoNT/E cannot bind to syntaxin and is released into the cytosol \[[@B189-toxins-02-00683],[@B200-toxins-02-00683]\].

To summarize, despite the scenario that the blocking actions of the various BoNTs differ at the molecular level, they all share several commonalities. Indeed, in all cases following toxin action, the formation or stability of the SNARE complex is compromised \[[@B201-toxins-02-00683],[@B202-toxins-02-00683]\], and it is no longer fusogenic. Thus, synaptic vesicles remain docked at the fusion sites with slightly increased numbers, suggesting that when tethered to the plasma membrane or docked in an unproductive complex, not only exocytosis but also undocking cannot proceed. Therefore, it is likely that synaptic vesicles docked with unproductive complexes can irreversibly plug the fusion sites that would normally accommodate intact vesicles.

### 3.1.4. Other consequences of SNARE cleavage

SNAREs are able to interact, directly or indirectly, with other proteins present in the plasma membrane. Their cleavage would indirectly affect the functioning of their partners. For example, syntaxin promotes inactivation of N- or P/Q-, R-, L-types Ca^++^ channels, and this inactivation is removed when proteins of the fusion complex (SNAP-25, VAMP, synaptotagmin...) bind to syntaxin and/or Ca^++^-channels \[[@B203-toxins-02-00683],[@B204-toxins-02-00683],[@B205-toxins-02-00683],[@B206-toxins-02-00683]\]. In this line, SNAP-25 has been reported to control calcium responsiveness to depolarization \[[@B122-toxins-02-00683]\]. Syntaxin cleavage may indirectly alter Ca^++^-channel functioning: slow Ca^++^ influx is potentiated after BoNT/C \[[@B207-toxins-02-00683]\], while in *Torpedo* preparations, Ca^++^ entry was reported to be significantly decreased by BoNT/C \[[@B208-toxins-02-00683]\]. Moreover, BoNT/C abolishes the regulation of Ca^++^-channel by heterotrimeric G-proteins \[[@B209-toxins-02-00683]\]. SNAP-25 modulates L-Type channels \[[@B210-toxins-02-00683]\], and entry of Ca^++^ mediated by store operated-channels in pancreatic acini secreting amylase, or human platelets. In these cells, Ca^++^ influx is strongly depressed after SNAP-25 cleavage by BoNT, possibly contributing to the blockade of Ca^++^-dependent exocytosis by BoNT/A \[[@B130-toxins-02-00683]\]. Note however that these non-neuronal effects have been detected using very high concentration of toxin (\~100 nM). Overall, these observations suggest that in certain preparations, the blockade of secretion resulting from SNAP-25 cleavage can be related to inhibition of the exocytotic machinery and changes in Ca^++^ influx at the nerve terminals. A significant reduction of the store operated Ca^++^ entry (SOCE) due to BoNT/A has been observed in different cells. SOCE normally follows a depletion of intracellular Ca^++^ stores ant this Ca^++^ influx is carried out by store-operated Ca^++^ channels (SOCC) \[[@B108-toxins-02-00683],[@B211-toxins-02-00683],[@B212-toxins-02-00683]\]. Working with *Xenopus* oocytes, Yao *et al.* demonstrated that the activation of a store-operated Ca^++^ current requires SNAP-25, since the current was found to be inhibited by BoNT/A in a dose-dependent manner with an apparent Ki of 8 nM. Similarly, the store-operated Ca^++^ current was almost completely abolished by expression of C-terminal truncated SNAP-25 mutants \[[@B213-toxins-02-00683]\]. BoNT/A L chain and TeNT significantly reduce SOCE when directly microinjected in human embryonic kidney (HEK) cells \[[@B214-toxins-02-00683]\]. SOCE is also significantly reduced by BoNT/A or BoNT/E in murine pancreatic acinar cells and in human platelets \[[@B130-toxins-02-00683],[@B131-toxins-02-00683]\]. The molecular identity of the channel carrying the Ca^++^ current in SOCE is in the process of clarification, then, it remains difficult to assert a role to SNAP-25 in the regulation of the conductance or in the process of protein secretion. A direct interaction of SNAP-25 with TRPC1 channel has been postulated \[[@B215-toxins-02-00683]\] and, more recently, the inhibition of exocytotic-like insertion of Orai1 into the plasma membrane in human HeLa and HEK 293T cells has been shown to be partially affected by BoNTA \[[@B216-toxins-02-00683]\]. Likewise, physical and functional interactions between syntaxin 1A and brain voltage gated K^+^ -channels Kv1.1 type have been found \[[@B217-toxins-02-00683]\]. The activity of Kv2.1 channel, the prevalent delayed rectifier channel in endocrine and neuroendocrine cells, is also strongly modulated by syntaxin and SNAP-25 \[[@B218-toxins-02-00683],[@B219-toxins-02-00683]\]. This suggests that SNARE proteins can regulate membrane excitability *via* K^+^ channels, thus tuning exocytosis. This raises the question of whether exocytosis may be altered by BoNTs *via* changes in activation of Kv2.1 currents.

### 3.1.5. Non-proteolytic molecular actions of BoNTs and TeNT

Yet a direct cause-effect relationship exists between the cleavage of the SNAREs and the blockade of neuroexocytosis by BoNTs or TeNT \[[@B41-toxins-02-00683],[@B44-toxins-02-00683],[@B220-toxins-02-00683]\]. A controversial possibility is that BoNTs and TeNT may interfere with exocytosis and other cell functions *via* molecular actions unrelated to their proteolytic activity. Indeed, when mutated in the catalytic site at positions crucial for either Zn^++^ binding (His233 and His237) or cleavage of the Gln-Phe bond in VAMP-2 (Glu234), TeNT L chain cannot cleave VAMP-2 *in vitro* \[[@B221-toxins-02-00683],[@B222-toxins-02-00683]\]. However, several of point-mutated TeNT L chain constructs are able to produce inhibition of neurotransmitter release (His233- \> Ala233, Leu233 or Val233; Glu234- \> Ala234; His237- \> Ala237; Asp237, Gly237 or Val237) albeit with reduced potency as compared to wild-type TeNT L chain \[[@B223-toxins-02-00683],[@B224-toxins-02-00683]\]. Such a non-proteolytic mechanism may explain why endopeptidase blockers, which abolish VAMP-2 cleavage *in vitro*, counteract only partially the inhibitory action of TeNT on neurotransmitter release \[[@B223-toxins-02-00683],[@B225-toxins-02-00683]\]. Moreover, the observation that antagonism of the intracellular action of BoNT/A can be relieved fast by the mean of injecting monoclonal antibodies directed against the BoNT/A L chain \[[@B226-toxins-02-00683]\] is difficult to conciliate with the proteloytic activity of the neurotoxin protein cleavage being in essence irreversible. The observation that TeNT binds with high affinity to, and strongly activates the GTP-binding protein transglutaminase type II (TGase II) *in vitro*, suggests that TGase II may participate in the intracellular action of TeNT \[[@B227-toxins-02-00683],[@B228-toxins-02-00683]\]. However, the precise contribution of TGase II to the blockade of neurotransmission by TeNT has never been clarified and conflicting data exist in the literature \[[@B223-toxins-02-00683],[@B229-toxins-02-00683],[@B230-toxins-02-00683]\]. TGase II belongs to a large family of bifunctional and Ca^++^-dependent cross-linking enzymes \[[@B231-toxins-02-00683],[@B232-toxins-02-00683]\] abundant in neurons and nerve endings \[[@B228-toxins-02-00683],[@B233-toxins-02-00683]\] which has been implicated in secretory mechanisms \[[@B234-toxins-02-00683],[@B235-toxins-02-00683],[@B236-toxins-02-00683]\].

The identification of the vesicular protein synapsin-I as one of the two main substrates crosslinked by TGase II needs to be considered for explaining part of the nonproteolytic TeNT-induced decrease in neurotransmitter release. Indeed, synapsin-I regulates synaptic vesicle trafficking *via* interactions with the actin cytoskeleton and participates in post-docking steps of exocytosis \[[@B237-toxins-02-00683],[@B238-toxins-02-00683]\]. Possibly, TeNT stimulation of TGase II leads to reduced synaptic vesicle availability for release. This view is supported by several observations: (i) the depolarization-stimulated phosphorylation and redistribution of synapsin-I is altered after the action of TeNT \[[@B239-toxins-02-00683]\]; (ii)the blocking action of TeNT is diminished after disassembly of microfilaments \[[@B150-toxins-02-00683]\] and (iii)the amplitude of post-tetanic potentiation, a plasticity paradigm which involves synapsin-I in *Aplysia* synapses, is highly reduced after TeNT treatment \[[@B36-toxins-02-00683],[@B237-toxins-02-00683]\]. As TeNT can access VAMP-2 only during a defined "physiological window" \[[@B41-toxins-02-00683],[@B44-toxins-02-00683]\], TGase-II activation may modulate this access *via* the modification of proteins involved in regulation of the synaptic vesicle cycle (*i.e.*, synapsin I) or its other substrate(s).

The importance of the proteolytic and non-proteolytic mechanisms of TeNT may be variable from one model systems to other, and may depend on differential expression of endogenous TGase-II. Contrasting with the observations made using brain synaptosomes or *Aplysia* preparations \[[@B223-toxins-02-00683],[@B224-toxins-02-00683]\], non-proteolytic TeNT mutants have been found ineffective at the mouse hemidiaphragm \[[@B221-toxins-02-00683]\] or neurohypophysial nerve endings \[[@B240-toxins-02-00683]\] and participation of TGase-II activation in the blockade of secretion by TeNT has been ruled out at the mouse neuromuscular junction and in NG108 cells \[[@B229-toxins-02-00683]\]. *In vitro*, BoNT/E light chain has been reported cleaving actin and all the 11 cleavages sites identified involved Arg or Lys residues in *P*'1 position exactly as in SNAP-25 \[[@B241-toxins-02-00683]\]. Thus another unexpected intracellular effect of TeNT is the modification of actin cytoskeleton. This is supported by several observations: TeNT inhibits the rearrangements of subcortical microfilaments that accompany secretion in chromaffin cells \[[@B242-toxins-02-00683]\]. Actin cytoskeleton network is altered when TeNT L chain is expressed in Sertoli cells in mice \[[@B243-toxins-02-00683]\]. Consistent with the well documented implication of small GTPases Rho in the dynamics and organization of actin-based cytoskeleton \[[@B24-toxins-02-00683]\], BoNT/A has been reported to target RhoB to the proteasome, causing both blockade of exocytosis and actin cystoskeleton disorganization \[[@B244-toxins-02-00683]\]. This may relate to a crosstalk between actin cytoskeleton remodeling, SNARE- and Rho-GTPase-dependent mechanisms of exocytosis, as illustrated for Cdc42 and VAMP-2 during insulin secretion \[[@B245-toxins-02-00683]\].

TeNT shows unconventional cellular action time before its classical proteolytic effects became evident. Aguliera and Yavin first reported the *in vivo* activation and translocation of protein kinase C in rat brain \[[@B246-toxins-02-00683]\]. Concomitantly, an increase of phosphoinositide hydrolysis was observed \[[@B247-toxins-02-00683]\]. The intracellular pathway activates phospholipase C-1 and other kinases \[[@B248-toxins-02-00683]\]. Among the different targets these enzymes can attain, the best characterized is the 5-HT transporter which is phosphorylated and has its activity modulated at low toxin concentration (10^--12^ M) in less than 30 minutes \[[@B155-toxins-02-00683],[@B157-toxins-02-00683],[@B158-toxins-02-00683]\]. These effects are carried out by the half C-terminal part of the H chain, the portion that carries the binding domain of the toxin to the receptor \[[@B249-toxins-02-00683],[@B250-toxins-02-00683]\]. It is of interest to note that this portion of the H chain is able to protect from death neuronal cells, *in vitro* as well as *in vivo* \[[@B250-toxins-02-00683],[@B251-toxins-02-00683],[@B252-toxins-02-00683]\]. Indeed, TeNT Hc activates phosphatidylinositol 3-kinase (PI-3K)/Akt (a serine/threonine kinase) as well as extracellular-signal regulated kinases 1 and 2 (ERK-1/2) pathways through phosphorylation of tyrosine kinase receptor leading to protection of apoptosis by preventing the proteolytic activation of pro-caspase-3, cytochrome c release from mitochondria, and chromatin condensation \[[@B249-toxins-02-00683],[@B251-toxins-02-00683],[@B253-toxins-02-00683]\]. Interestingly, TeNT Hc prevents apoptosis induced by 1-methyl-4-phenylpyridinium (MPP+), which is a mitochondrial poison used to reproduce a Parkinson-like disease \[[@B251-toxins-02-00683]\]. Since TeNT Hc is retrogradely transported to the central nervous system it could be used in the prevention/treatment of the Parkinson\'s disease. *In vivo* in a rat model of Parkinson\'s disease, TeNT HC has been found to improve the dopaminergic system and to enhance the survival rate \[[@B252-toxins-02-00683]\].

3.2. Toxins which inactivate Rho-GTPases and inhibit neuroexocytosis
--------------------------------------------------------------------

### 3.2.1. Glucosylating clostridial toxins

Glucosylating clostridial toxins, also known as the large clostridial toxins such as *Clostridium sordellii* lethal toxin (LT) and *Clostridium difficile* toxin A (ToxA) and toxin B (ToxB), inactivate Rho-and/or Ras-GTPases by modifying a conserved threonine within the effector domain of target molecules. ToxB catalyzes glucosylation of Rho proteins (Rho, Rac, and Cdc42), whereas the several variants of LT modify Rac, sometimes Cdc42, and various Ras proteins (*i.e.*, Ras, Rap, Ral). *C. difficile* and *C. sordellii* toxins use UDP-glucose as cosubstrate, and *Clostridium novyi* α-toxin uses UDP-*N*-acetylglucosamine. GDP-bound GTPase is the preferred substrate, since the modified Thr35 and Thr37 residues are only exposed on the surface of this GTPase form.

Although glucosylated GTPases can bind to their target membrane and undergo GDP-GTP exchange when stimulated by guanylate exchange factors, modification of Thr37/35 which is localized within switch I of GTPases, prevents the interaction with their effectors. In addition, intrinsic GAP (GTPase activating protein)-stimulated GTPase activity is reduced, inhibiting the GDP-GTP cycling of modified GTPases between the membrane and cytosol. Thereby, glycosylated GTPases act as dominant negative mutants \[[@B254-toxins-02-00683],[@B255-toxins-02-00683],[@B256-toxins-02-00683],[@B257-toxins-02-00683],[@B258-toxins-02-00683],[@B259-toxins-02-00683],[@B260-toxins-02-00683]\].

*C. botulinum* C3 enzyme is an ADP-ribosyltransferase, which specifically inactivates Rho. C3 ADP-ribosylates Asn41, which is localized within the switch I loop near Thr37. C3-mediated ADP-ribosylation of Rho inhibits the GTPase translocation to the membrane and therefore prevents the interaction with its effectors. ADP-ribosylated Rho is trapped by guanine dissociation inhibitor (GDI) in an inactive, cytosolic form \[[@B24-toxins-02-00683],[@B260-toxins-02-00683],[@B261-toxins-02-00683],[@B262-toxins-02-00683]\].

### 3.2.2. Neuronal alterations caused by toxin inactivation of Rho GTPases

Several small GTPases of the Ras superfamily are present in nerve terminals and include RhoA, RhoB, Rac1, and Cdc42. Additionally, Rac1 associates with synaptic vesicles as well as with plasma membrane \[[@B27-toxins-02-00683],[@B28-toxins-02-00683]\]. The Ral molecule also binds to synaptic vesicles \[[@B31-toxins-02-00683]\]. Intraneuronal application of C3 exoenzyme, ToxB from *C. difficile*, or LT from *C. sordellii* blocks Ca^++^-dependent vesicular ACh release from *Aplysia* synapses \[[@B27-toxins-02-00683],[@B28-toxins-02-00683]\]. LT exhibits the highest activity upon neurotransmitter release, being 100--1,000 fold more potent than ToxB or the C3-exoenzyme \[[@B27-toxins-02-00683]\]. Similarly, LT blocks spontaneous glutamate release in cultured rat cerebellar slices (Kojima and Poulain, unpublished observation). These observations are consistent with reports that Rho-acting toxins block the secretory process in many cell types, including mast cells \[[@B263-toxins-02-00683],[@B264-toxins-02-00683],[@B265-toxins-02-00683],[@B266-toxins-02-00683]\]. In muscles isolated from mice previously injected with LT, nerve-evoked muscle twitch is blocked. This effect results from both a presynaptic block of ACh release and depressed muscle contractility \[[@B267-toxins-02-00683]\].

This is consistent with the high lethality of LT (\~0.3 × 10^6^ mouse LD50/mg protein) injected intraperitoneally, which is due to respiratory failure \[[@B268-toxins-02-00683]\]. Because of the potent blocking action of LT on nerve endings, a question arises whether the intestinal disorders which characterize enterotoxemia caused by clostridia producing Rho-acting toxins are linked to intestinal epithelial damage and/or stimulation of the enteric nervous system \[[@B269-toxins-02-00683]\]? Identity of the downstream pathways whose silencing blocks exocytosis induced by LT or ToxB has been addressed in different cell systems. Apparently, the affected pathways can vary in different cell types. In several types of secretory cells, experimental findings indicate that the toxins induce remodeling of the actin cytoskeleton, thereby altering intracellular granule trafficking towards the plasma membrane, which possibly includes fusion \[[@B265-toxins-02-00683],[@B266-toxins-02-00683]\]. Another interesting configuration has been deciphered in RBL-mast cells. In these cells, exocytosis is triggered by a rise in intracellular Ca^++^ levels induced by stimulation of either the Fc-epsilon receptor or muscarinic- type AChR. The Rac GTPase is the only one involved in Ca^++^ mobilization within these cells, and the blockade of exocytosis by ToxB or LT is due to inhibition of capacitative Ca^++^ entry exclusively through store-operated Ca^++^ channels \[[@B263-toxins-02-00683],[@B270-toxins-02-00683]\].

In nerve endings, the blockade of neurotransmitter exocytosis caused by ToxB and LT appears to have another origin. Studies performed with *Aplysia* cholinergic synapses reveal that following inactivation of Rac by LT or ToxB, the exocytosis process starts normally, but then stops, possibly during the priming events. This results in a dramatic decrease in the number of functional release sites \[[@B28-toxins-02-00683]\], which is very similar to the gross action of TeNT or BoNTs. What is the role of Rac during priming? Rac, Rho, Cdc42, Ral, and PLD1 all participate in a multiprotein complex termed "exocyst," which is comprised of Sec6/Sec8 proteins and regulates polarized secretion as well as docking of vesicles to plasma membrane regions specialized in exocytosis \[[@B271-toxins-02-00683]\]. Therefore, one cannot exclude that Rho-acting toxins block exocytosis by disabling exocyst function in nerve endings. However, implication of an exocyst role during exocytosis of neurotransmitter is disputed. Alike, possibility implicating PLD1 in the exocytosis process is that by catalyzing PA generation, the formation of lipid bilayer intermediates becomes favored during membrane fusion. PLD1 activity is inhibited in LT-poisoned cells \[[@B272-toxins-02-00683]\], and Rac plus Cdc42 regulate PLD1 activity \[[@B273-toxins-02-00683]\]. The intraneuronal application of a catalytically- inactive mutant of PLD1 reproduces the potent inhibitory effect of LT \[[@B237-toxins-02-00683]\]. Therefore, we envisage the following model for LT and ToxB action at the presynapse, which initially involves glucosylation of Rac by the toxins, thus preventing activation of PLD1 upon synaptic vesicle docking. Production of fusogenic PA is not stimulated, and despite the Ca^++^ influx triggering SNARE complex zippering, fusion of synaptic vesicle with plasmalemma exocytosis cannot occur because the lipid composition at release sites remains inadequate. The synaptic vesicles equipped with modified Rac plug exocytosis sites and prevent fusion of synaptic vesicles equipped with intact Rac ([Figure 2](#toxins-02-00683-f002){ref-type="fig"}). This contributes to the reduced numbers of active release sites induced by LT or ToxB. In addition to the presynaptic actions mentioned above, clostridial cytotoxins affecting Rho GTPases can also block neurotransmission by altering postsynaptic cell capabilities to detect transmitter. For example, neurotransmitter-receptor density is diminished in neurons treated with toxins that affect Rac or Cdc42 \[[@B274-toxins-02-00683]\]. The observation that LT prevents long-term potentiation \[[@B275-toxins-02-00683]\] is consistent with inhibiting insertion of new receptors into the post-synaptic membrane. Note that it is not yet clear whether changes in receptor density refer to the role of Rho proteins during the exocytotic process, which includes receptor insertion into the plasma membrane, and/or organization of the post-synaptic actin cytoskeleton involved in receptor clustering \[[@B276-toxins-02-00683]\].

Much evidence suggests that apoptosis plays a crucial role in cell homeostasis, which depends upon the expression of various genes implicated in controlling life and death. Incubation of rat primary cerebellar granule neurons in culture with either ToxB or LT reportedly induces cell death with biochemical and morphological hallmarks of neuronal apoptosis \[[@B277-toxins-02-00683]\]. In these cells, selective inhibition of Rac/Cdc42 function promotes: (1) phosphorylation and expression of the transcription factor c-Jun; (2) activation of caspase-3; and (3) nuclear condensation, as well as fragmentation. Interestingly, apoptosis occurs independently of F-actin-cytoskeletal disruption, since agents that directly disassemble F-actin (*C. botulinum* C2 toxin, cytochalasin D, and latrunculin A) do not induce cell death within 24 h. These results indicate that Rac/Cdc42 GTPases are critical for survival of cerebellar granule neurons in primary culture. Additionally, these data are the first to establish a prosurvival function for Rho GTPases in a primary neuronal cell model.

3.3. Toxins which damage neuronal cells, neuronal apoptosis
-----------------------------------------------------------

*Strpetococcus pneumoniae* (or *Pneumococcus*) is the most common cause of bacterial meningitis, which is characterized by neuronal cell death in the hippocampus as well as by an inflammatory response. Pneumolysin (PLY) produced by *S. pneumoniae*, is one of the virulence factors leading to neuronal cell damages and which also causes injury to pulmonary alveolar epithelial cells \[[@B278-toxins-02-00683]\].

PLY (53 kDa) is a pore-forming toxin from the cholesterol-dependent cytolysin family, the prototype of which is the perfringolysin (PFO) from *C.* *perfringens*. PLY shares 45% identity at the amino acid level with PFO. In contrast to PFO, PLY contains no signal sequence for secretion and is released mainly during autolysis of bacteria \[[@B279-toxins-02-00683]\]. A structural model of PLY based on the high similarity with PFO shows that PLY has an unusual elongated rod shape. The molecule is rich in β-sheet and it is hydrophilic without significant patches of hydrophobic residues on the surface. Four domains can be distinguished in the PFO or PLY molecule. Domain 1 has a seven-stranded antiparallel β-sheet and is connected to domain 4 by the elongated domain 2. Domain 3 consists of β-sheets and α-helices. The C-terminal part (domain 4) folds into a separate and compact β-sandwich domain, and contains three loops (L1-L3), which are involved in the binding to choleterol \[[@B280-toxins-02-00683],[@B281-toxins-02-00683]\].

A unique Cys is located in a conserved 11 amino acid sequence (ECTGLAWEWWR) near the C-terminus, in the domain 4, which participates to the prepore to pore conversion \[[@B280-toxins-02-00683],[@B282-toxins-02-00683]\]. The proposed model of PFO pore formation, which is probably similar to that of PLY, includes the binding of water soluble PFO monomers to cholesterol of lipid bilayer mediated by the L1-L3 loops from domain 4 \[[@B280-toxins-02-00683]\]. But, domain 4 does not insert deeply into the membrane and is not directly involved in creating the pore. PFO monomers bound to cholesterol and orientated perpendicularly to the membrane assemble and oligomerize to form a prepore complex \[[@B283-toxins-02-00683]\]. Oligomers consist of 40 to 50 monomers forming on the membrane surface large arcs and rings leading to large pores between 300 Å and 450 Å in diameter \[[@B284-toxins-02-00683]\]. Domains 1, 2 and 4 fit into L-shaped repeating units connected to the corresponding domains of the neighboring partners and forming a cylindrical structure. Oligomer formation results from domain 1-domain-1 interaction *via* hydrogen bonding between 1-strand of one subunit with 4-strand of a second subunit. Interaction of domain 4 with cholesterol induces a conformational change of domain 1 causing the moving of β5-strand which prevents 1-4 interaction in the soluble PFO form and thus permitting the oligomerization process only when PFO interact with cell membrane \[[@B285-toxins-02-00683],[@B286-toxins-02-00683]\]. Thereby, PFO monomers do not oligomerize in solution. In addition, domains 3 are rotated from domains 2 and form a belt in the outside face of the cylinder. This is accompanied by a flexing of domain 2 leading to a loss of many contacts between domain 3 and domain 2 thus promoting the exposure of hydrohobic residues and the insertion of a transmembrane β-barrel into the lipid bilayer \[[@B287-toxins-02-00683],[@B288-toxins-02-00683],[@B289-toxins-02-00683]\]. A bundle of three α-helices of domain 3 unfolds forming two amphipathic β-sheets. Each monomer contributes two amphipathic β-hairpins to the formation of the transmembrane β-barrel \[[@B290-toxins-02-00683],[@B291-toxins-02-00683]\]. Monomers do not insert their transmembrane hairpins individually, but a cooperation between PFO monomers is required to drive the insertion of the prepore complex, which appears to be an all or none process \[[@B292-toxins-02-00683]\]. The charged face of domain 4 amphipathic β-hairpin forms the inner lining of the pore and the other face is protected from the hydrophobic part of the lipid bilayer by cholesterol molecules \[[@B293-toxins-02-00683]\]. Domain 2 collapses vertically of 40 Å allowing the insertion of the β-barrel into the membrane and formation of a large membrane pore \[[@B294-toxins-02-00683]\].

An initial step in bacterial meningitis is the passage of *S. pneumoniae* from blood to the brain through the blood brain barrier. PLY is probably involved in this process, since PLY expressing strain but not PLY negative mutant is able to penetrate into microvascular endothelial cells. The mechanism of PLY-dependent translocation of bacteria across the cell barrier is possibly based on loss of cell viability and cell detachment \[[@B278-toxins-02-00683],[@B295-toxins-02-00683]\]. Subsequently in the central nervous system, PLY directly induces hippocampal neuronal cell death *via* an apoptotic process. Indeed, PLY was found to colocalize with damaged neurons in the hippocampus and to mediate microglia and neuronal cell apoptosis *in vitro* \[[@B296-toxins-02-00683]\]. The PLY pore-forming activity is required to trigger apoptosis in primary hippocampal neurons, whereas the PLY domain involved in complement activation is not required. The PLY-dependent pathway leading to neuronal cell apoptosis includes an increase in Ca^++^ into the cytosol subsequently to an influx from extracellular space and a release from endoplasmic-reticulum stores, mitochondrial damages with release of cytochrome *c* and AIF (apoptosis inducing factor) and then DNA fragmentation \[[@B296-toxins-02-00683],[@B297-toxins-02-00683]\]. The increase in intracellular Ca^++^ seems to be mainly mediated by toxin-dependent pore formation in cell membranes and is followed by an activation of p38 MAPK (mitogen-activated protein kinase) and possibly by opening of the mitochondrial permeability transition pore leading to AIF release \[[@B298-toxins-02-00683]\]. However, PLY also directly interacts with mitochondria as evidenced by colocalization of PLY with mitochondrial membranes, and can possibly directly forms pores in mitochondria. PLY apoptosis is caspase-independent and is mediated by the release of mitochondrial AIF, which is a potent caspase-independent cell death factor \[[@B296-toxins-02-00683],[@B297-toxins-02-00683]\]. Thus PLY is a pore-forming toxin inducing apoptosis in hippocampal neuronal cells in addition to damages caused in other cell types.

4. Toxins Which Stimulate Neurosecretion
========================================

4.1. Stimulation of glutamate release: Clostridium perfringens epsilon toxin
----------------------------------------------------------------------------

Epsilon toxin acts on different cell types, including those of neuronal origin. It is not a strict neurotoxin as defined previously for BoNTs and TeNT, but epsilon toxin is involved in neurological symptoms. Epsilon toxin represents the major virulence factor of *C. perfringens* types B and D, which are the etiological agents of fatal enterotoxemia in sheep as well as goats, and more rarely of cattle. Overgrowth of *C. perfringens* in the intestine of susceptible animals, generally a consequence of overeating high starch/sugar-containing foods, results in large amounts of epsilon toxin. The toxin is absorbed through the intestinal mucosa by opening tight junctions between intestinal epithelial cells and spreads into different organs by the circulatory system \[[@B299-toxins-02-00683],[@B300-toxins-02-00683]\], ultimately causing hypertension, increased vascular permeability, lung edema, and post mortem kidney necrosis (pulpy kidney disease in lambs) \[[@B260-toxins-02-00683],[@B301-toxins-02-00683],[@B302-toxins-02-00683]\]. The disease is rapidly fatal with neurological disorders that include excitation symptoms. Major pathological changes are observed in the brain following epsilon intoxication, which include: congestion and edema of the meninges, perivascular and intercellular edema, as well as necrotic foci of the nervous tissue. Epsilon toxin passes through the blood brain barrier and accumulates specifically in the brain \[[@B303-toxins-02-00683],[@B304-toxins-02-00683]\]. The toxin damages endothelial cells of the blood-brain barrier by altering the endothelial barrier antigen localized to luminal endothelial cell membranes, thus causing leakage of endogenous albumin \[[@B305-toxins-02-00683]\]. The specific receptor for epsilon toxin on neuronal and endothelial cells is not yet known, although a membrane sialoglycoprotein seemingly mediates toxin binding \[[@B304-toxins-02-00683],[@B306-toxins-02-00683]\]. In the brain, epsilon toxin increases vascular permeability leading to a rapid, severe, and diffuse edema that exerts a direct cytotoxic effect upon neurons. Neuronal damage is characterized by progressive cytoplasmic vacuolization plus necrosis, and in some cells there is hyperchromatosis and nuclear pyknosis \[[@B307-toxins-02-00683]\]. The neurological disorders linked to epsilon toxin, which likely result from an excessive release of glutamate, include retraction of the head, opisthotonus, convulsions, agonal struggling, and hazardous roaming. Indeed, epsilon toxin injected intravenously into mice preferentially excitates hippocampal neurons that induce an increased glutamate efflux which can be blocked by a specific inhibitor \[[@B308-toxins-02-00683],[@B309-toxins-02-00683]\].

The molecular basis for epsilon neurotoxicity is not known, but the toxin is a pore former, which structurally mimics *Aeromonas hydrophila* aerolysin \[[@B310-toxins-02-00683]\]. Epsilon-toxin retains an elongated form and contains three domains, which are mainly composed of β-sheets. The overall structure is significantly related to that of the pore forming toxin aerolysin. The main difference between both toxins is that the aerolysin domain I, which is involved in initial toxin interaction with cells, is missing in epsilon-toxin. Domain 1 of epsilon-toxin consists in a large α-helix followed by a loop and three short α-helices and is similar to domain 2 of aerolysin which interacts with the GPI anchors of proteins. This domain of epsilon-toxin could have a similar function of binding to receptor. Domain 2 is a β-sandwich structurally related to domain 3 of aerolysin. This domain contains a two-stranded sheet with an amphipatic sequence which is the channel-forming domain \[[@B311-toxins-02-00683]\]. Domain 3 is also a β-sandwich analogous to domain 4 of aerolysin and contains the cleavage site for toxin activation. Domain 3 after removing of the C-terminus is likely involved in monomer-monomer interaction required for oligomerization \[[@B312-toxins-02-00683]\].

In Madine Darby Canine Kidney (MDCK) cells, which is a rare cell line sensitive to epsilon toxin, the toxin recognizes a specific unknown receptor, heptamerizes, and forms pores that lead to an efflux of K^+^, influx of Na^+^, Cl^−^ and Ca^++^, cell swelling, and membrane blebbing/disruption \[[@B313-toxins-02-00683],[@B314-toxins-02-00683],[@B315-toxins-02-00683]\]. In addition, epsilon toxin rapidly decreases membrane barrier permeability of polarized MDCK cells \[[@B316-toxins-02-00683]\]. Epsilon toxin also forms heptamers in synaptosomal membranes \[[@B313-toxins-02-00683],[@B317-toxins-02-00683]\], which involves detergent resistant membrane microdomains called lipid rafts. But it is not yet defined whether the toxin-induced glutamate release is due to pore formation or another specific mechanism.

The epsilon toxin-dependent cytotoxicity is associated with a rapid loss of intracellular K^+^, and an increase of Cl^−^ and Na^+^, whereas the increase of Ca^++^ occurs later. In addition, the loss of viability also correlates with the entry of propidium iodide, indicating that the epsilon-toxin forms large pores in cell membrane. Pore formation was evident in artificial lipid bilayer. Epsilon-toxin induces water-filled channels permeable to hydrophilic solutes up to a molecular mass of 1 kDa, which represent general diffusion pores slightly selective for anions \[[@B315-toxins-02-00683]\]. In polarized MDCK cells, epsilon-toxin induces a rapid and dramatic increase in permeability. Pore formation in the cell membrane is likely responsible for the permeability change of cell monolayers. Actin cytoskeleton and organization of tight and adherens junctions are not altered, and the paracellular permeability to macromolecules is not significantly increased upon epsilon-toxin treatment \[[@B318-toxins-02-00683],[@B319-toxins-02-00683]\]. Epsilon toxin causes a rapid cell death by necrosis characterized by a marked reduction in nucleus size without DNA fragmentation. Toxin-dependent cell signaling leading to cell necrosis is not yet fully understood and includes ATP depletion, AMP-activated protein kinase stimulation, mitochondrial membrane permeabilization, and mitochondrial-nuclear translocation of AIF \[[@B319-toxins-02-00683]\]. Therefore, epsilon-toxin is a very potent toxin, which alters the permeability of cell monolayers such as epithelium and endothelium causing edema and cell death and which induces glutamate release from hippocampal neuronal cells.

4.2. Stimulation of serotonin release and other neuromediators from the enteric nervous system
----------------------------------------------------------------------------------------------

Increasing evidence suggests that some enterotoxins mediate diarrhea by not only acting directly upon enterocytes, but also by interfering/stimulating the enteric nervous system \[[@B269-toxins-02-00683]\]. The enteric nervous system is comprised of the myenteric plexus which is primarily involved in motor control of the gut and of the submucosal plexus, which plays a central role in sensing the chemical status of the intestine and in regulating secretion. Neuronal cell bodies of the enteric nervous system (intrinsic afferent neurons, interneurons, motor- and secretory-neurons) are clustered in ganglia and connected to parasympathetic and sympathetic systems. More than 20 neurotransmitters have been identified in the enteric nervous system. Among them, substance P, ACh, GABA, glutamate, and 5-HT modulate motility, absorption, and secretion of the intestine \[[@B320-toxins-02-00683],[@B321-toxins-02-00683]\].

### 4.2.1. Bacterial enterotoxins inducing increased intestinal secretion

#### 4.2.1.1. Cholera toxin

Cholera toxin (CT) is produced by *Vibrio cholerae* and is responsible for cholera, which is a serious epidemic disease characterized by severe diarrhea and dehydration. CT consists of an A or enzymatic subunit (28 kDa), and 5 B or binding subunits (11 kDa each) assembled in a pentamer (AB5 structure). The A subunit is proteolytically activated by a *V.* *cholerae* endopeptidase into two components A1 (approximately 22 kDa) and A2 (approximately 5.5 kDa) which remain linked by a disulfide bridge. The carboxy-terminal part of A2 extends through the central pore of the B pentamer and is linked non-covalently to the B subunits. Heat labile enterotoxin (HLT) from *Escherichia coli* is highly similar to CT, 88% amino acid sequence homology and closely related crystalline structure \[[@B322-toxins-02-00683]\]. However, LT induces a much less severe type of diarrhea.

Both toxins, CT and HLT, recognize the glycosphingolipid GM1 on enterocyte membrane. CT entry into cell and intracellularr trafficking has been extensively studied. The whole toxin bound to GM1 receptors is then internalized into endocytic vesicles \[[@B323-toxins-02-00683]\]. GM1 directs the toxin into lipid-rafts from where it enters the Golgi *via* early and late endosomes \[[@B324-toxins-02-00683]\]. CT enters cells *via* multiple ways including clathrin-dependent and --independent pathways. But transport of CT from plasma membrane to Golgi is mainly mediated by endosomes containing caveolin-1 and is independent of clathrin coated-pits \[[@B325-toxins-02-00683]\]. In the perinuclear region of the Golgi, the A subunit dissociates from the B subunits and enters the endoplasmic reticulum *via* coatomer I-coated vesicles and uses the cell secretion system Sec60/61. The carboxy-terminal sequence of the A2 fragment contains an endoplasmic reticulum (ER) retention sequence (KDEL), which may rather function to efficiently retain the toxins in the ER, allowing the A1 chain to be transported into the cytosol \[[@B326-toxins-02-00683],[@B327-toxins-02-00683]\].

The A1 fragment is responsible for the enzymatic activities of the toxin, including NAD hydrolysis in ADP-ribose and nicotinamide, and covalent transfer of ADP-ribose to Arg-187 of the subunit of stimulatory protein (Gs leading to stimulation of adenylate cyclase and elevated intracellular cAMP \[[@B324-toxins-02-00683]\]. The increased cAMP levels induces an activation of protein kinase A, which subsequently phosphorylates numerous substrates in the cell including the major chloride channel called the cystic fibrosis transmembrane conductance channel (CFTR). This results in an active Cl^−^ secretion and a decrease of NaCl-coupled absorption by enterocytes \[[@B322-toxins-02-00683],[@B324-toxins-02-00683]\].

But in addition, CT stimulates 5-HT release from enterochromaffin cells primarily localized at the base of the epithelial crypts of the intestine, probably *via* its effect on adenylate cyclase activation. Increased intracellular cAMP activates Ca^++^ influx through L-type calcium channel resulting in exocytosis of 5-HT containing granules \[[@B328-toxins-02-00683]\]. Indeed, an increased 5-HT release into the intestinal tissue and lumen was evidenced in response to CT in human and animal models, as well as an inhibition of CT-dependent intestinal secretion by pharmacological inhibitors of 5-HT receptors. A direct binding of CT to enterochromaffin cells seems to trigger the degranulation and 5-HT release \[[@B329-toxins-02-00683]\]. Thus, 5-HT~2~, 5-HT~3~ and 5-HT~4~ receptors have been found to be involved in CT-mediated intestinal secretion \[[@B329-toxins-02-00683],[@B330-toxins-02-00683],[@B331-toxins-02-00683],[@B332-toxins-02-00683],[@B333-toxins-02-00683],[@B334-toxins-02-00683]\]. 5-HT receptors are classified in seven families and are distributed on enterocytes, myocytes and neurons of the gastrointestinal tract. Except the 5-HT~3~ receptor, which is a ligand-gate ion channel, the other 5-HT receptors are seven-transmembrane domain G-protein-coupled receptors. 5-HT~2~ receptors are located to myenteric and submucosal neurons, enterocytes, and longitudinal and circular muscle cells of the gastrointestinal tract. They participate to intestinal motility and to intestinal secretion *via* an arachidonic pathway. 5-HT~3~ receptors are expressed in neurons of myenteric and submucosal plexus, interstitial cells of Cajal, and muscle fibers of circular and longitudinal muscles, as well as in submucosa and mucosa. Activation of 5-HT~3~ receptors results in gastrointestinal contractions and intestinal chloride secretion, and in 5-HT release from enterochromaffin cells. 5-HT~4~ receptors have been identified in submucosal and myenteric plexus as well as in nerve fibers of intestinal circular muscles. 5-HT~4~ receptors have an important role in gastrointestinal functions such as activation of gastrointestinal motricity *via* enhancement of ACh and CGRP release as well as stimulation of chloride and bicarbonate secretion by enterocytes \[[@B335-toxins-02-00683]\]. Therefore, CT-induced intestinal secretion is mediated by 5-HT release from enterochromaffin cells and in part from enteric neurons by the toxin ([Figure 1](#toxins-02-00683-f001){ref-type="fig"}). Released 5-HT induces water and electrolyte secretion *via* stimulation of 5-HT~2~ receptors on enterocytes and *via* activation of secretory reflex(es) through the enteric nervous system. 5-HT activates afferent sensory nerves mainly through stimulation of 5-HT~3~ and 5-HT~4~ receptors. These afferent neurons, probably from the submucosal plexus, contain ACh/substance P, ACh/CGRP, and dynorphin or glutamate as neurotransmitters. They project to the myenteric plexus and are also directly connected to secretomotor neurons \[[@B336-toxins-02-00683],[@B337-toxins-02-00683],[@B338-toxins-02-00683]\]. Indeed, CT-induced secretion can be blocked by the ACh nicotinic receptor antagonist hexamethonium, by substance P antagonists as well as by inhibitors of substance P receptors such as neurokinin-1 and neurokinin-2 \[[@B5-toxins-02-00683],[@B338-toxins-02-00683]\].

Cholinergic interneurons and possibly other interneurons containing other neurotransmitters probably connect the myenteric and the submucosal neurons of the reflex, which subsequently stimulate efferent secretory neurons releasing VIP and possibly nitric oxide (NO). VIP is a potent intestinal secretagogue, which recognizes specific receptors belonging to the type B G-protein coupled receptor family, on the basolateral membrane of crypt cells as well as of many other cell types, and induces an adenyl cyclase-cAMP-dependent secretion of NaCl and water. VIP triggers increase in camp level only in crypt cells and not in villus cells. camp activates protein kinase A and subsequently a phosphorylation cascade leading to stimulation of the apical CFTR channel and chloride secretion \[[@B5-toxins-02-00683],[@B336-toxins-02-00683]\]. Antagonists of 5-HT, substance P and VIP markedly reduce CT-induced secretion \[[@B320-toxins-02-00683],[@B337-toxins-02-00683],[@B338-toxins-02-00683]\]. In addition, ACh is a calcium-dependent chloride secretagogue through activation of muscarinic receptors such as M3 or possibly through a direct delivery into epithelial cells and seems to be also involved in the CT induced intestinal secretion \[[@B5-toxins-02-00683]\]. Therefore, CT probably stimulates the two types of efferent neurons of the intestinal secretory reflex pathway, cholinergic and VIP neurons contributing to the toxin induced diarrhea ([Figure 3](#toxins-02-00683-f003){ref-type="fig"}).

Interestingly, *E. coli* HLT does not stimulate the release of 5-HT from enterochromaffin cells. Thereby, HLT-induced secretion is not inhibited by inhibitors of 5-HT or substance P. However, lignocaine and the ganglionic blocker hexamethonium have a preventive effect, suggesting that the entero nervous system is also involved in the enteric activity of HLT, but *via* a distinct pathway than that mediated by 5-HT. Although highly related to CT, HLT exhibits significant structural differences and recognizes a low affinity glycoprotein receptor. This might account for the non activation of enterochromaffin cells by HLT and the 5-HT-mediated intestinal secretion induced by CT explains, at least partially, the severity of cholera versus the more moderate diarrhea caused by HLT \[[@B320-toxins-02-00683],[@B329-toxins-02-00683]\].

#### 4.2.1.2. Enterotoxins modifying the actin cytoskeleton or inducing an intracellular second messenger

*C. difficile* toxin A (ToxA; \~300 kDa) is a potent enterotoxin responsible for pseudomembranous colitis. In addition to the apparent actin-cytoskeleton alterations in enterocytes like ToxB, ToxA probably uses a neural mechanism to increase intestinal secretion ([Figure 3](#toxins-02-00683-f003){ref-type="fig"}). Lignocaine, hexamethonium, and substance P inhibitors can block Tox A-induced ileal fluid accumulation, mucosal permeability, and inflammation \[[@B339-toxins-02-00683]\]. It is proposed that ToxA stimulates primary sensory neurons in the intestinal mucosa, causing subsequent release of substance P and CGRP, which then facilitates intestinal secretion and inflammation. These neuropeptides bind to macrophages in the lamina propria and activate the release of proinflammatory cytokines such as tumor necrosis factor (TNF) \[[@B269-toxins-02-00683],[@B340-toxins-02-00683]\]. Thereby, ToxA stimulates intestinal macrophage expression of neurokinin-1, which is a high affinity receptor for substance P, and additionally neurokinin-1 deficient mice are protected from ToxA-induced intestinal secretion and inflammatory diarrhea \[[@B341-toxins-02-00683]\]. Neurotensin, a gastrointestinal neuropeptide, is also involved since an inhibitor of neurotensin prevents the secretory and inflammatory responses following ToxA exposure \[[@B342-toxins-02-00683]\]. Furthermore, ToxA also suppresses noradrenaline release at sympathetic synapses of the enteric nervous system that play an inhibitory effect on secretomotor neurons, thus amplifying mucosal secretion \[[@B343-toxins-02-00683]\]. It is not yet clear whether ToxA directly stimulates intestinal sensory neurons by a mechanism involving Rho proteins, or indirectly *via* inflammatory mediators released from enterocytes or other cells such as macrophages in response to ToxA.

![.Schematic model of the neuronal reflex controlling the intestinal secretion and alteration by enterotoxins. Cholera toxin (CT) triggers the release of serotonin (5-HT) from enterochromaffin cells, mainly located in intestinal crypts, which stimulates enterocyte secretion through 5-HT~2~ receptors and activates afferent sensory neurons through 5-HT~3~, 5-HT~4~ receptors. The neuronal signal is relayed through the submucosal and myenteric plexuses leading to activation of secretomotor neurons including acetylcholine (ACh) and vaso-intestinal peptide (VIP) neurons. ACh stimulates M2 receptors on enterocytes and VIP recognizes specific enterocyte receptors. The neuronal-dependent intestinal secretion is negatively regulated by noradrenergic and enkephalinergic neurons. *C.* *difficile* ToxA stimulates primary sensory neurons leading to the release of substance P (SP) and calcitonin gene-related protein (CGRP) and subsequently causing intestinal secretion and inflammation. ToxA first interacts with intestinal epithelial cells causing actin cytoskeleton alteration and release of cytokines, which are probably the stimulators of primary sensory neurons. In addition, ToxA attenuates the inhibitory response of noradrenergic and enkephalinergic neurons. The precise ToxA pathway permitting its interaction with the enteric nervous system is not yet known.](toxins-02-00683-g003){#toxins-02-00683-f003}

*C.* *perfringens* enterotoxin (CPE) is responsible for the food borne intoxication due to this bacterium. CPE is synthesized during the sporulation of *C.* *perfringens* and is a pore-forming toxin which binds to specific receptors on enterocyte membranes which have been identified to claudins leading to loss of fluid and electrolytes \[[@B344-toxins-02-00683]\]. In addition, CPE interacts with nerve endings. Thereby, CPE has been found to bind to presynaptic nerve endings in mouse phrenic nerve-diaphragm, possibly at synaptophysin sites and to inhibit neurotransmission. CPE seems to block the neuroexocytosis process, by a yet unidentified mechanism \[[@B345-toxins-02-00683]\]. The role of CPE interaction with the enteric nervous system in the diarrhea development is still unknown.

The much smaller *E. coli* heat stable enterotoxins (STa; 2--5 kDa) activate guanylate cyclase, increase cyclic guanosine monophosphate (cGMP) levels, and subsequently open Cl^−^ channels. Since STa-induced secretion is blocked by tetrodotoxin, lignocaine, hexamethonium, and also by capsaicin and vagotomy, the entero nervous system also likely supports STa activity \[[@B320-toxins-02-00683],[@B346-toxins-02-00683]\]. The exact mechanism of activation of the enteric nervous system by STa is still elusive. VIP antagonist partially prevents STa-induced secretion indicating that VIPergic neurons are involved in STa enteric activity \[[@B347-toxins-02-00683]\]. However in contrast to cholera toxin, STa seems not to stimulate 5-HT release \[[@B330-toxins-02-00683],[@B348-toxins-02-00683]\]. But, STa would activate a NO-dependent myenteric plexus secretory reflex mediated by capsain sensitive C fibers \[[@B346-toxins-02-00683],[@B348-toxins-02-00683]\]. VIP and NO seem to have a synergetic effect since NO releases VIP from nerve terminals and VIP seems to induce the release of nitric oxide, and both VIP and NO could participate in STa enteric activity \[[@B330-toxins-02-00683]\]. STa might also activate neurokinin receptor NK2 to induce intestinal secretion \[[@B349-toxins-02-00683]\].

### 4.2.2. Emetic toxins

#### 4.2.2.1. *Bacillus cereus* cereulide

*Bacillus cereus* is a common foodborne pathogen, which causes two types of gastrointestinal diseases in humans, the diarrhoeal and the emetic syndromes. The diarrhoeal disease is due to enterotoxins, which are multicomponent toxins produced *in situ* subsequently to an over proliferation of *B. cereus* in the small intestine, whereas the emesis syndrome results from ingestion of a *B. cereus* emetic toxin, named cereulide, which accumulates in contaminated foods \[[@B350-toxins-02-00683]\].

Cereulide is a cyclic dodecadepsipeptide (1.2 kDa) which is synthesized by a nonribosomal peptide synthetase \[[@B351-toxins-02-00683],[@B352-toxins-02-00683],[@B353-toxins-02-00683]\]. Cereulide is produced by only certain *B. cereus* strains which are associated to the emetic syndrome \[[@B354-toxins-02-00683]\]. The toxin is stable to acid conditions, proteolysis and heat, and thus it is not degraded by gastric acid and digestive proteases. Cereulide is cytotoxic, it induces mitochondria swelling (reported first as vacuole formation) in Hep2 cells and necrotic cell death in porcine pancreatic Langherans cells, as well as causes emesis in experimental animal models \[[@B355-toxins-02-00683],[@B356-toxins-02-00683],[@B357-toxins-02-00683],[@B358-toxins-02-00683]\]. Cytotoxicity towards various primary or cultured cell lines has been reported \[[@B359-toxins-02-00683]\]. The mechanism of action of cereulide is only partially known. Cereulide is a K^+^ ionophore similarly to valinomycin, as evidenced by selective increase in K^+^ permeability of phospholipids bilayers induced by the toxin \[[@B360-toxins-02-00683]\]. Both toxins are also structurally related \[[@B352-toxins-02-00683]\]. While valinomycin is more potent at high K^+^ concentration (120 mM), cereulide is more active than valinomycin at low K^+^ concentrations (1--3 mM) which corresponds to the physiological level in blood serum. Cereulide promotes K^+^ uptake by mitochondria, efflux of H^+^, drop in the transmembrane inner potential, leading to mitochondria swelling, arrest of respiratory function, inhibition of ATP synthesis, and release of proapoptotic or necrotic factors \[[@B360-toxins-02-00683],[@B361-toxins-02-00683],[@B362-toxins-02-00683]\]. The emetic effects of cereulide seems to be dependent of stimulation of 5-HT~3~ receptors on vagal afferent neurons since 5-HT~3~ receptor antagonist such as ondanserom hydrochloride or vagotony inhibits the emetic effect in suncus \[[@B352-toxins-02-00683]\]. It is not known whether cereulide directly interacts with vagal sensory endings or releases 5-HT from enterochromaffin cells.

#### 4.2.2.2. *Staphylococcus* enterotoxins

*Staphylococcus aureus* produces a myriad of 25--30 kDa, single-chain proteins called the *staphylococcal enterotoxins* (SEs) \[[@B363-toxins-02-00683]\]. These potent toxins cause a prevalent form of food poisoning found throughout the world, and these molecules also possess "superantigenic" properties. By classic definition, this latter property involves binding to both major histocompatibility complex class II (MHC II) on antigen presenting cells and V-specific T-cell receptors, which ultimately cause massive T-cell proliferation with a concomitant uncontrolled production/release of various proinflammatory cytokines. To date, it is uncertain if superantigenicity plays a direct role in SE-induced food poisoning. However, levels of inflammatory mediators like prostaglandins and leukotrienes are increasingly evident in the circulatory system of non-human primates shortly after an oral dose of SE type B (SEB) \[[@B364-toxins-02-00683]\]. Mast cells may also play a role in SE-induced food poisoning, which perhaps involves not only inflammatory mediators, but also stimulation by neuropeptides like substance P released from sensory neurons \[[@B365-toxins-02-00683]\]. Another study reveals that SEB-induced effects in mice (intraperitoneal injection) are abrogated by capsaicin, the active ingredient of hot chili peppers, which depletes peptidergic sensory nerve fibers and TNF production \[[@B366-toxins-02-00683]\]. An intraperitoneal injection of SEB into rats induces expression of Fos (a cell activator) throughout the brain *via* vagus nerve stimulation, thus suggesting that the peripheral presence of an SE has profound effects upon the brain \[[@B367-toxins-02-00683]\]. More recently, it has been reported that SE type A (SEA)--induced emesis is mediated by 5-HT. Indeed, emesis caused by SEA in animal model (house musk shrew) is inhibited by 5-HT synthesis inhibitor and a 5-HT~3~ receptor antagonist, and in addition SEA increases 5-HT release in the intestine. The mechanism of 5-HT release mediated by SEA is not yet known. SEA might interact directly with enterochromaffin cells or neurons to trigger 5-HT release, or could act indirectly through the release of proinflammatory molecules or free-radical formation \[[@B368-toxins-02-00683]\]. Mucosal terminals of vagal sensory afferent neurons, which project to the emetic center in the brainstem contains 5-HT~3~ receptors \[[@B335-toxins-02-00683]\]. The proposed model includes a SEA-dependent excess release of 5-HT in the intestine and subsequent stimulation of 5-HT~3~ receptors on vagal afferent neurons triggering the emesis ([Figure 1](#toxins-02-00683-f001){ref-type="fig"}) \[[@B368-toxins-02-00683]\].

5. Conclusions
==============

Is neurotoxicity a unique, inherent function of a bacterial toxin? Most bacterial proteins with demonstrable "toxic" activity, such as those presented in this review, interact with various cell types. For example, more than one third of all bacterial toxins are pore-formers that recognize ubiquitous membrane components as receptors, such as cholesterol, gangliosides, and proteins. These toxins can indiscriminately damage membranes from different cells, including those of neuronal origin. Among them, *C. perfringens* epsilon toxin has the fundamental structure of a pore-forming toxin, is cytotoxic for kidney epithelial cells, and also possesses specific neurotoxic activity. However, a specific neurotoxic mechanism of action and trafficking pattern targeting neuronal cells by epsilon toxin during the natural course of disease still remains undetermined. Other toxins have developed various internalization processes, therefore specifically modifying an intracellular target. Thus, several bacterial proteins like the large clostridial toxins (*C. sordellii* LT and *C. difficile* ToxA/ToxB) have the ability to bind/enter various cell types that include those of neuronal origin. Large clostridial toxins inactivate intracellular targets like Rho and/or Ras GTPases, which are involved in multiple signaling pathways. Among them, Rac controls the neuroexocytosis process. Thereby, large clostridial toxins efficiently block neurotransmitter release, although they do not specifically target neuronal cells. Involvement of their neurotoxic activity during disease, which is often overcome by toxic effects upon other cell types in natural pathology, is also a function of a toxin's opportunity to enter neuronal cells near the infection site. Various bacterial enterotoxins, which have developed a specific mode of interaction with enterocytes, amplify their intestinal activity by stimulating the secretomotor reflex from the enteric nervous system, like CT, or interact with distinct nervous afferences on the intestinal mucosa leading to vomiting. It is noteworthy that the enteric nervous system is a preferential target for many bacterial toxins, which transit through the intestinal tract. Finally, two unique classes of neurotoxins, BoNTs and TeNT, have evolved as specific inhibitors of the neuroexocytosis machinery. These bacterial proteins recognize specific receptors on neuronal cells and only interfere intracellularly with highly specialized molecules, like the SNARE proteins, which play a pivotal role in evoked release of neurotransmitter. It is intriguing that toxins produced by environmental bacteria, which are not normally adapted for a commensal life with higher organisms and only interact accidentally with them, possess such specific and highly sophisticated tools. What is the underlying selective pressure for such evolution from a bacterial protease to a neurotoxin? Perhaps neurotoxins simply result from an evolutionary process independent of the host. What is the inherited benefit derived by an environmental bacterium to produce a neurotoxin, which apparently does not recognize other bacterial or environmental substrates? Clearly, we approach this from a scientist's (human) perspective, and with such an inherent bias that it may be difficult and virtually impossible to truly understand this natural curiosity. During their evolution, clostridial pathogens have developed a potent arsenal of noxious proteins that affect the central and peripheral nervous system of various vertebrates. These commonly named neurotoxins specifically target some key functions, or cellular processes, of eukaryotic cells, which subsequently cause a wide array of life-threatening diseases in humans and animals. These neurotoxins bind to specific receptors in the plasma membrane of susceptible host cells and translocate their enzymatically active domains/subunits into the cytosol, where finally they elicit the deleterious effects commonly associated with the holotoxins. Modes of action for the neurotoxic proteins reviewed here have been deciphered during the last decade, and now a clearer picture of their intracellular substrates is emerging. The specificity of these toxic proteins has enabled them to become useful tools to elucidate and characterize crucial processes for eukaryotic cells, which include neurotransmitter release, physiological signaling pathways, and constitutive cellular mechanisms. However, additional studies are needed to completely identify their specific membrane-receptors, as well as comprehend the mechanisms and structures involved in toxin routing throughout the nervous system. Thus, multidisciplinary approaches integrating molecular microbiology, membrane biology, biochemistry, physiology, proteomics, and pharmacology will further advance our understanding of the transport mechanisms required for directing molecules to specific locations within the nervous system of eukaryotes. Clearly, specificity of action for the BoNTs has made them very useful therapeutic agents for many human neurological syndromes caused by hyperactivity of cholinergic nerve terminals. It is expected that future pharmacological developments will employ the inherent capabilities of various toxins to deliver biologically-active substances into nerve cells.
